prednisolone has been researched along with Myasthenia Gravis in 252 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effectiveness of cladribine treatments in a population of patients with refractory myasthenia gravis (MG)." | 9.34 | Cladribine in myasthenia gravis: a pilot open-label study. ( Baranowski, D; Korchut, A; Rejdak, K; Szklener, S, 2020) |
| "Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction, and prednisolone (PSL) and immunosuppressive drugs are available for treatment." | 9.15 | Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. ( Doi, S; Fujiki, N; Kikuchi, S; Minami, N; Niino, M; Sasaki, H; Shima, K, 2011) |
| "To evaluate the ability of tacrolimus to reduce the corticosteroid dose in patients with myasthenia gravis (MG) and the drug's safety in a double-blind, placebo-controlled, parallel group study." | 9.15 | Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. ( Kiuchi, T; Saida, T; Takamori, M; Yoshikawa, H, 2011) |
| "To clarify the long-term efficacy, safety and the cytokine network-modulating effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed consecutive patients and nine steroid-dependent patients were retrospectively reviewed, and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile." | 9.13 | Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. ( Furukawa, Y; Iwasa, K; Yamada, M; Yoshikawa, H, 2008) |
| "To examine the long-term effects of tacrolimus in steroid-dependent myasthenia gravis (MG) patients." | 9.13 | Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. ( Kuroda, Y; Nagaishi, A; Yukitake, M, 2008) |
| "We prospectively investigated therapeutic and adverse effects of tacrolimus in seven patients with myasthenia gravis (MG) who were resistant to conventional therapies or could not be treated with thymectomy because of complications." | 9.12 | Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone. ( Gono, T; Ikeda, S; Ishii, W; Matsuda, M; Shimojima, Y; Tokuda, T, 2006) |
| "To elucidate the long-term therapeutic efficacy and safety of low-dose FK506 (tacrolimus) in patients with myasthenia gravis (MG)." | 9.12 | Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. ( Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006) |
| "Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0." | 9.11 | Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. ( Armengol, M; Azem, J; Codina, A; Fort, JM; Montoro, JB; Ponseti, JM, 2005) |
| "We observed that oral administration of 3 mg tacrolimus daily for 1 year can significantly improve the clinical symptoms of patients with refractory myasthenia gravis, which is characterized by a significant reduction in clinical scores, such as QMG, MMT, ADL, MGQOL-15, and a reduction daily oral prednisolone (PSL) dose (P < 0." | 8.12 | Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. ( Chen, L; Wu, H; Wu, Y; Xue, Q; Yan, Y; Zhao, C; Zhou, X; Zhu, Y, 2022) |
| "Several clinical studies using tacrolimus revealed reasonable therapeutic mechanisms and efficacy in patients with myasthenia gravis (MG)." | 7.85 | A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. ( Ahn, SW; Cho, EB; Hong, YH; Joo, IS; Kang, SY; Kim, BJ; Min, JH; Minn, YK; Nam, TS; Oh, J; Oh, SY; Park, JS; Park, YE; Seok, HY; Seok, JI; Seok, JM; Shin, HY; Shin, JY; Suh, BC; Sung, JJ, 2017) |
| "A single, oral dose of 3 mg/day tacrolimus, approved for myasthenia gravis (MG) treatment in Japan, was shown to reduce steroid dose and anti-acetylcholine receptor (AChR) antibody titers as well as to improve MG symptoms." | 7.85 | Adequate tacrolimus concentration for myasthenia gravis treatment. ( Himuro, K; Kanai, T; Kawaguchi, N; Kuwabara, S; Oda, F; Ozawa, Y; Uzawa, A, 2017) |
| "This study aimed to investigate the benefits of administering perioperative high-dose prednisolone in conjunction with thymectomy in patients with myasthenia gravis." | 7.79 | Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients. ( Iwata, T; Kawaguchi, N; Mizobuchi, T; Suzuki, H; Tagawa, T; Yamada, Y; Yoshida, S; Yoshino, I, 2013) |
| " Cyclosporin A therapy quickly improved myasthenia gravis symptoms in all cases, which allowed a rapid reduction in the prednisolone dose and improvement of prednisolone-related hyperglycemia and hypertension." | 7.79 | Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. ( Fujita, K; Kaneko, S; Kusaka, H; Morita, J; Nakamura, S; Nakano, S; Shinde, A, 2013) |
| "We describe a case of recurrent invasive thymoma associated with myasthenia gravis that responded to combined treatment with prednisolone and tacrolimus." | 7.76 | Combined treatment with prednisolone and tacrolimus for myasthenia gravis with invasive thymoma. ( Aizawa, H; Ayabe, M; Azuma, K; Kage, M; Kawahara, A; Miura, S; Noda, K; Takamori, S; Taniwaki, T; Yamada, K, 2010) |
| "Severe autoimmune myasthenia gravis is difficult to manage and may require immunosuppression with cyclosporine." | 7.74 | Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. ( Chambers, B; Donnan, G; Ierino, FL; Lim, AK, 2007) |
| "The purpose of this study was to clarify the clinical benefits of perioperative administration of high-dose prednisolone (PSL) combined with extended thymectomy on the long-term outcomes of 116 consecutive patients with generalized myasthenia gravis (MG)." | 7.73 | Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis? ( Fujisawa, T; Hamada, C; Iyoda, A; Kawaguchi, N; Sekiguchi, H; Sekine, Y; Shibuya, K; Yasufuku, K, 2006) |
| "Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone." | 7.72 | Bone density in myasthenia gravis patients receiving long-term prednisolone therapy. ( Araki, Y; Hayashi, N; Konno, S; Nakazato, A; Nemoto, H; Nomoto, N; Sugimoto, H; Wakata, N, 2004) |
| " Both disorders had been controlled for around 15 years by oral prednisolone and a cholinesterase inhibitor following surgical removal of invasive thymoma and radiotherapy, but muscular weakness due to myalgia and an increase in serum levels of myogenic enzymes, mainly ascribable to the recurrence of PM, reappeared immediately after cessation of these drugs, which was done because the patient had multiple bone fractures and severe osteoporosis due to the long-term corticosteroid therapy." | 7.72 | Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. ( Gono, T; Hoshi, K; Ikeda, S; Matsuda, M; Shimojima, Y; Yamamoto, K; Yoshida, K, 2004) |
| "We treated two patients suffering from intractable myasthenia gravis (MG) with low-dose tacrolimus plus prednisolone." | 7.71 | Low-dose tacrolimus for intractable myasthenia gravis. ( Mabuchi, K; Takamori, M; Yamada, M; Yasukawa, Y; Yoshikawa, H, 2002) |
| "Azathioprine is an established immunosuppressive agent in the treatment of myasthenia gravis." | 7.69 | [Myasthenic crisis caused by azathioprine-induced fever]. ( George, A; Nau, R; Tumani, H, 1997) |
| "Twenty-seven patients with myasthenia gravis have been treated with azathioprine in conjunction with pyridostigmine and prednisolone for a total of 138 patient years." | 7.68 | Long term treatment of myasthenia gravis with azathioprine. ( Fonseca, V; Havard, CW, 1990) |
| "Administration of anti-cholinesterase before operation and high doses of prednisolone after the operation are commonly prescribed in cases of thymectomy for the treatment of myasthenia gravis." | 7.67 | Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis. ( Baba, M; Obata, S; Saito, Y; Yamaguchi, Y, 1987) |
| "Ten patients with myasthenia gravis (MG) were treated with weekly plasma exchange (PE) in combination with prednisone and azathioprine; 4 of the patients were treated with 3-6 PE alone, before instituting prednisone/azathioprine." | 7.66 | Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone/azathioprine in myasthenia gravis. ( Miller, RG; Milner-Brown, HS, 1982) |
| "Electrophysiological investigations of the effects of bath-applied prednisolone at the neuromuscular junction were performed in muscles from normal rats and rats with experimental autoimmune myasthenia gravis (EAMG)." | 7.66 | Short-term effects of prednisolone on neuromuscular transmission in normal rats and those with experimental autoimmune myasthenia gravis. ( Goldner, MM; Kim, YI; Sanders, DB, 1979) |
| "The aim of this study was to assess the effectiveness of cladribine treatments in a population of patients with refractory myasthenia gravis (MG)." | 5.34 | Cladribine in myasthenia gravis: a pilot open-label study. ( Baranowski, D; Korchut, A; Rejdak, K; Szklener, S, 2020) |
| "Tacrolimus is a new immunosuppressive agent acting through the selective inhibition of helper-T-cell activation that can be reduced dosage of steroids and can maintain remission of myasthenia gravis with invasive thymoma." | 5.33 | Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy. ( Deguchi, K; Ikeda, K; Kuriyama, S; Sasaki, I; Shimamura, M; Takeuchi, H; Touge, T; Tsukaguchi, M; Urai, Y, 2005) |
| "Several treatments for alopecia areata including administration of systemic prednisolone were attempted, but loss of hair on the scalp progressed." | 5.30 | Alopecia areata associated with myasthenia gravis and thymoma: a case of alopecia with marked improvement following thymectomy and high level prednisolone administration. ( Hatamochi, A; Kamada, N; Shinkai, H, 1997) |
| "Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction, and prednisolone (PSL) and immunosuppressive drugs are available for treatment." | 5.15 | Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. ( Doi, S; Fujiki, N; Kikuchi, S; Minami, N; Niino, M; Sasaki, H; Shima, K, 2011) |
| "To evaluate the ability of tacrolimus to reduce the corticosteroid dose in patients with myasthenia gravis (MG) and the drug's safety in a double-blind, placebo-controlled, parallel group study." | 5.15 | Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. ( Kiuchi, T; Saida, T; Takamori, M; Yoshikawa, H, 2011) |
| "To clarify the long-term efficacy, safety and the cytokine network-modulating effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed consecutive patients and nine steroid-dependent patients were retrospectively reviewed, and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile." | 5.13 | Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. ( Furukawa, Y; Iwasa, K; Yamada, M; Yoshikawa, H, 2008) |
| "To examine the long-term effects of tacrolimus in steroid-dependent myasthenia gravis (MG) patients." | 5.13 | Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. ( Kuroda, Y; Nagaishi, A; Yukitake, M, 2008) |
| "We prospectively investigated therapeutic and adverse effects of tacrolimus in seven patients with myasthenia gravis (MG) who were resistant to conventional therapies or could not be treated with thymectomy because of complications." | 5.12 | Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone. ( Gono, T; Ikeda, S; Ishii, W; Matsuda, M; Shimojima, Y; Tokuda, T, 2006) |
| "To elucidate the long-term therapeutic efficacy and safety of low-dose FK506 (tacrolimus) in patients with myasthenia gravis (MG)." | 5.12 | Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. ( Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006) |
| "Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0." | 5.11 | Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. ( Armengol, M; Azem, J; Codina, A; Fort, JM; Montoro, JB; Ponseti, JM, 2005) |
| "Prednisolone, 6-mercaptopurine, and pyridostigmine bromide are co-administered together to treat a neuromuscular autoimmune disease called myasthenia gravis." | 4.31 | Tailoring Two Chemometric Models for Determination of Three Neuromuscular Combined Medications and Application to Spiked Human Plasma. ( Abdelhamid, NS; Anwar, BH; Farid, NF; Magdy, MA, 2023) |
| "We investigated the efficacy of low-dose prednisolone (PSL) regimen in patients with generalized myasthenia gravis (MG) post-thymectomy and its correlation with long-term outcome." | 4.12 | Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy. ( Li, F; Wang, T; Yan, X; Yu, H; Zhang, Y; Zhu, H, 2022) |
| "We observed that oral administration of 3 mg tacrolimus daily for 1 year can significantly improve the clinical symptoms of patients with refractory myasthenia gravis, which is characterized by a significant reduction in clinical scores, such as QMG, MMT, ADL, MGQOL-15, and a reduction daily oral prednisolone (PSL) dose (P < 0." | 4.12 | Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. ( Chen, L; Wu, H; Wu, Y; Xue, Q; Yan, Y; Zhao, C; Zhou, X; Zhu, Y, 2022) |
| "Stress-induced hyperlactatemia and subsequent myasthenic crisis INTERVENTIONS:: Pyridostigmine and immunosuppressive therapy with prednisolone were initiated." | 3.96 | Myasthenic crisis and late deep vein thrombosis following thymectomy in a patient with myasthenia gravis: A case report. ( Chen, JY; Cheng, WJ; Chiang, MH; Chu, CC; Ho, CN; Hung, KC; Liao, SW; Lin, CY; Liu, WC; Sun, CK; Tsai, IT, 2020) |
| "We examined the correlation between the dosing regimen of oral prednisolone (PSL) and the achievement of minimal manifestation status or better on PSL ≤5 mg/day lasting >6 months (the treatment target) in patients with generalised myasthenia gravis (MG)." | 3.88 | Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. ( Akaishi, T; Aoki, M; Imai, T; Kawaguchi, N; Konno, S; Masuda, M; Minami, N; Murai, H; Nagane, Y; Suzuki, H; Suzuki, Y; Tsuda, E; Utsugisawa, K; Uzawa, A, 2018) |
| "Several clinical studies using tacrolimus revealed reasonable therapeutic mechanisms and efficacy in patients with myasthenia gravis (MG)." | 3.85 | A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. ( Ahn, SW; Cho, EB; Hong, YH; Joo, IS; Kang, SY; Kim, BJ; Min, JH; Minn, YK; Nam, TS; Oh, J; Oh, SY; Park, JS; Park, YE; Seok, HY; Seok, JI; Seok, JM; Shin, HY; Shin, JY; Suh, BC; Sung, JJ, 2017) |
| "A single, oral dose of 3 mg/day tacrolimus, approved for myasthenia gravis (MG) treatment in Japan, was shown to reduce steroid dose and anti-acetylcholine receptor (AChR) antibody titers as well as to improve MG symptoms." | 3.85 | Adequate tacrolimus concentration for myasthenia gravis treatment. ( Himuro, K; Kanai, T; Kawaguchi, N; Kuwabara, S; Oda, F; Ozawa, Y; Uzawa, A, 2017) |
| "The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG)." | 3.81 | Oral corticosteroid therapy and present disease status in myasthenia gravis. ( Fujihara, K; Imai, T; Konno, S; Masuda, M; Murai, H; Nagane, Y; Nakane, S; Suzuki, N; Suzuki, S; Suzuki, Y; Tsuda, E; Utsugisawa, K, 2015) |
| "We herein investigated the clinical features of three patients with anti-muscle-specific tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG), which was initially difficult to distinguish from amyotrophic lateral sclerosis (ALS)." | 3.81 | Anti-MuSK Antibody-positive Myasthenia Gravis Mimicking Amyotrophic Lateral Sclerosis. ( Fujita, Y; Furuta, N; Ikeda, M; Ikeda, Y; Ishizawa, K; Makioka, K; Motomura, M; Nagamine, S; Okamoto, K; Shibata, M; Tsukagoshi, S; Yoshimura, S, 2015) |
| " He presented with a high level of serum vascular endothelial growth factor (VEGF) and RS3PE syndrome-like pitting edema in the extremities, which improved following treatment with low-dose prednisolone." | 3.80 | Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis. ( Honda, M; Horai, Y; Ichinose, K; Kawakami, A; Kawashiri, SY; Motomura, M; Nakamura, H; Nakashima, Y; Nishino, A; Origuchi, T; Suzuki, T; Tamai, M, 2014) |
| " Two weeks postremoval, the cat developed myasthenia gravis, which was controlled with prednisolone and pyridostigmine." | 3.79 | Putative paraneoplastic pemphigus and myasthenia gravis in a cat with a lymphocytic thymoma. ( Brain, P; Collins, D; Fearnside, S; Hill, PB; Olivry, T, 2013) |
| "This study aimed to investigate the benefits of administering perioperative high-dose prednisolone in conjunction with thymectomy in patients with myasthenia gravis." | 3.79 | Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients. ( Iwata, T; Kawaguchi, N; Mizobuchi, T; Suzuki, H; Tagawa, T; Yamada, Y; Yoshida, S; Yoshino, I, 2013) |
| " Cyclosporin A therapy quickly improved myasthenia gravis symptoms in all cases, which allowed a rapid reduction in the prednisolone dose and improvement of prednisolone-related hyperglycemia and hypertension." | 3.79 | Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. ( Fujita, K; Kaneko, S; Kusaka, H; Morita, J; Nakamura, S; Nakano, S; Shinde, A, 2013) |
| "In treating myasthenia gravis (MG), our aims were to achieve early minimal manifestations (MM) by performing early aggressive therapy (EAT) using plasmapheresis and high-dose intravenous methylprednisolone, and then to maintain the status with low-dose oral corticosteroids (EAT strategy)." | 3.77 | Early aggressive treatment strategy against myasthenia gravis. ( Nagane, Y; Suzuki, N; Suzuki, S; Utsugisawa, K, 2011) |
| "An 85-year-old man with myasthenia gravis was successfully treated with methotrexate (10 mg/week), pyridostigmine and prednisolone (0-30 mg/day) for over 10 years." | 3.77 | Candida esophagitis as the cause of swallowing disturbances in an 85-year-old patient with myasthenia gravis. ( Ebert, S; Nau, R; Schweiger, KP, 2011) |
| "We describe a case of recurrent invasive thymoma associated with myasthenia gravis that responded to combined treatment with prednisolone and tacrolimus." | 3.76 | Combined treatment with prednisolone and tacrolimus for myasthenia gravis with invasive thymoma. ( Aizawa, H; Ayabe, M; Azuma, K; Kage, M; Kawahara, A; Miura, S; Noda, K; Takamori, S; Taniwaki, T; Yamada, K, 2010) |
| "We studied the long-term crisis-preventing effect of combined prednisolone-azathioprine (PR-AZA) treatment in myasthenia gravis (MG)." | 3.75 | Long-term effects of combined immunosuppressive treatment on myasthenic crisis. ( Illes, Z; Kasa, K; Komoly, S; Mikor, A; Rózsa, C, 2009) |
| "Severe autoimmune myasthenia gravis is difficult to manage and may require immunosuppression with cyclosporine." | 3.74 | Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. ( Chambers, B; Donnan, G; Ierino, FL; Lim, AK, 2007) |
| "Myasthenic patients with diabetes mellitus could be classified into 2 groups, one group with positive organ-specific autoantibodies to many organs (with type 1 diabetes mellitus), and the other group with diabetes mellitus onset during prednisolone administration (with type 2 diabetes mellitus)." | 3.74 | Myasthenia gravis and diabetes mellitus: a 35-year retrospective study. ( Konno, S; Kurihara, T; Nakazora, H; Nemoto, H; Nomoto, N; Sugimoto, H; Wakata, N, 2007) |
| "The purpose of this study was to clarify the clinical benefits of perioperative administration of high-dose prednisolone (PSL) combined with extended thymectomy on the long-term outcomes of 116 consecutive patients with generalized myasthenia gravis (MG)." | 3.73 | Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis? ( Fujisawa, T; Hamada, C; Iyoda, A; Kawaguchi, N; Sekiguchi, H; Sekine, Y; Shibuya, K; Yasufuku, K, 2006) |
| "Extended thymectomy and high-dose alternate-day prednisolone administration may increase the chance of remission in myasthenia gravis (MG) patients." | 3.72 | Relapse of ocular symptoms after remission of myasthenia gravis--a comparison of relapsed and complete remission cases. ( Iguchi, H; Kurihara, T; Nomoto, N; Sugimoto, H; Wakata, N, 2003) |
| "Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone." | 3.72 | Bone density in myasthenia gravis patients receiving long-term prednisolone therapy. ( Araki, Y; Hayashi, N; Konno, S; Nakazato, A; Nemoto, H; Nomoto, N; Sugimoto, H; Wakata, N, 2004) |
| " Both disorders had been controlled for around 15 years by oral prednisolone and a cholinesterase inhibitor following surgical removal of invasive thymoma and radiotherapy, but muscular weakness due to myalgia and an increase in serum levels of myogenic enzymes, mainly ascribable to the recurrence of PM, reappeared immediately after cessation of these drugs, which was done because the patient had multiple bone fractures and severe osteoporosis due to the long-term corticosteroid therapy." | 3.72 | Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. ( Gono, T; Hoshi, K; Ikeda, S; Matsuda, M; Shimojima, Y; Yamamoto, K; Yoshida, K, 2004) |
| "We treated two patients suffering from intractable myasthenia gravis (MG) with low-dose tacrolimus plus prednisolone." | 3.71 | Low-dose tacrolimus for intractable myasthenia gravis. ( Mabuchi, K; Takamori, M; Yamada, M; Yasukawa, Y; Yoshikawa, H, 2002) |
| "We report 2 cases of thymomatous myasthenia gravis associated with postoperative crisis and medicated with steroid therapy using prednisolone without primary dose escalation." | 3.71 | Steroid therapy without primary dose escalation for postthymectomy crisis in 2 thymomatous myasthenia gravis patients. ( Fujiwara, K; Hasegawa, K; Inoue, M; Kimura, K; Nakagawa, K; Yasumitsu, T, 2002) |
| " Polymyositis was diagnosed, and prednisolone was administered." | 3.69 | [Polymyositis followed by myasthenia gravis]. ( Fukusako, T; Morimatsu, M; Negoro, K; Nogaki, H; Saeki, S, 1996) |
| "Azathioprine is an established immunosuppressive agent in the treatment of myasthenia gravis." | 3.69 | [Myasthenic crisis caused by azathioprine-induced fever]. ( George, A; Nau, R; Tumani, H, 1997) |
| "Ninety-five patients with generalized myasthenia gravis were followed for 10 years to evaluate the long term effects of prednisolone, thymectomy, or both, and they were compared with a group only with anticholinesterase treatment." | 3.68 | Treatment of myasthenia gravis: a comparison of the natural course and current therapies. ( Motomura, M; Nagataki, S; Seto, M; Takeo, G; Tsujihata, M; Yoshimura, T, 1993) |
| "Twenty-seven patients with myasthenia gravis have been treated with azathioprine in conjunction with pyridostigmine and prednisolone for a total of 138 patient years." | 3.68 | Long term treatment of myasthenia gravis with azathioprine. ( Fonseca, V; Havard, CW, 1990) |
| "Administration of anti-cholinesterase before operation and high doses of prednisolone after the operation are commonly prescribed in cases of thymectomy for the treatment of myasthenia gravis." | 3.67 | Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis. ( Baba, M; Obata, S; Saito, Y; Yamaguchi, Y, 1987) |
| "Ten patients with myasthenia gravis (MG) were treated with weekly plasma exchange (PE) in combination with prednisone and azathioprine; 4 of the patients were treated with 3-6 PE alone, before instituting prednisone/azathioprine." | 3.66 | Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone/azathioprine in myasthenia gravis. ( Miller, RG; Milner-Brown, HS, 1982) |
| "Short-term, high-dose steroids (prednisolone sodium succinate) were given to female Lewis rats in the chronic stage of experimental autoimmune myasthenia gravis (EAMG)." | 3.66 | Steroid treatment for experimental autoimmune myasthenia gravis. ( Barone, DA; Lambert, DH; Poser, CM, 1980) |
| "Electrophysiological investigations of the effects of bath-applied prednisolone at the neuromuscular junction were performed in muscles from normal rats and rats with experimental autoimmune myasthenia gravis (EAMG)." | 3.66 | Short-term effects of prednisolone on neuromuscular transmission in normal rats and those with experimental autoimmune myasthenia gravis. ( Goldner, MM; Kim, YI; Sanders, DB, 1979) |
| "A marked protective action of the corticosteroids prednisolone, hydrocortisone, and dexamethasone has been shown on a hypothetical model of myasthenia gravis, using the rat phrenic nerve-diaphragm preparation treated with hemicholinium-3." | 3.65 | Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis. ( Leeuwin, RS; Wolters, MJ, 1976) |
| "The tapering of prednisone therapy in generalized myasthenia gravis (MG) presents a therapeutic dilemma; however, the recommended regimen has not yet been validated." | 3.01 | Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial. ( Birnbaum, S; Clair, B; Demeret, S; Eymard, B; Friedman, D; Grimaldi, L; Gueguen, A; Nadaj-Pakleza, A; Porcher, R; Sharshar, T; Spinazzi, M; Tranchant, C, 2021) |
| "While thymolipomas are often seen in the context of myasthenia gravis, thyrolipomatosis is a rare entity and to our knowledge the concurrent finding of both lesions with myasthenia gravis has never been reported." | 2.72 | Concurrent thyrolipomatosis and thymolipoma in a patient with myasthenia gravis: a case report and review of the literature. ( Adams, A; Ali, S; Campion, T; Maity, A; Richards, P, 2021) |
| "Mean azathioprine dose was reduced concomitantly from 89 +/- 9." | 2.70 | Long-term treatment of myasthenia gravis with immunoadsorption. ( Derfler, K; Goldammer, A; Haas, M; Mayr, N; Zeitlhofer, J, 2002) |
| "Myasthenia gravis is one of the most satisfying neurological disorders to treat." | 2.44 | When the patient fails to respond to treatment: myasthenia gravis. ( Hilton-Jones, D, 2007) |
| "Myasthenia gravis is caused by antibodies against acetylcholine receptors and is treated with inhibition or elimination of antibody production." | 2.41 | [A case of myasthenia gravis, who developed minimal change nephrotic syndrome during immunosuppressive therapy after thymectomy]. ( Inoue, Y; Matsuda, O; Takahashi, K; Takemura, T; Yoshimura, A, 2000) |
| "Juvenile myasthenia gravis is relatively rare in toddlers." | 1.62 | "Mummy, my eyelids are heavy": A case series of juvenile myasthenia gravis. ( Abdul Jalil, NF; Choo, MM; Krishna, L; Lott, PW; Singh, S, 2021) |
| "The patient presented with right-sided congestive heart failure of unknown etiology, necessitating hospitalization on three occasions over a 6-month period." | 1.56 | [A case of anti-MuSK positive MG with recurrent right-sided heart failure as the initial manifestation]. ( Matsumoto, Y; Shima, K; Shimizu, A; Yamaguchi, K, 2020) |
| "Treatment with pyridostigmine bromide, prednisone, and tacrolimus was initiated." | 1.56 | Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection. ( Wang, Y; Wen, Y; Yang, J; Zhao, N, 2020) |
| "Good syndrome is the association of thymoma with combined B cell and T cell immunodeficiency." | 1.51 | Thymoma complicated with myasthenia gravis and Good syndrome - a therapeutic conundrum: a case report. ( Chang, T; De Silva, R; Handagala, S; Paranavitane, S, 2019) |
| "Treatment with prednisolone rapidly ameliorated the symptoms, and the serum CK level normalized." | 1.51 | [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]. ( Fujita, N; Isami, A; Kawachi, I; Shimaoka, Y; Suzuki, S; Uchiyama, A, 2019) |
| "A 36-year-old woman with RA and generalized myasthenia gravis (MG) developed RM during a remission phase." | 1.48 | Rheumatoid meningitis developed in patient with stable rheumatoid arthritis and myasthenia gravis-detailed analysis of intracranial inflammation using flow cytometry. ( Fujita, Y; Fujita-Nakata, M; Kawai, U; Matsui, M; Nagayama, S; Nakanishi, M; Oono, M; Sanada, M; Uchida, N, 2018) |
| " Dosing regimens of oral steroids in EFT produced no differences in the time course." | 1.46 | Early fast-acting treatment strategy against generalized myasthenia gravis. ( Akaishi, T; Aoki, M; Imai, T; Kawaguchi, N; Konno, S; Masuda, M; Minami, N; Murai, H; Nagane, Y; Suzuki, H; Suzuki, Y; Tsuda, E; Utsugisawa, K; Uzawa, A, 2017) |
| "Myasthenia gravis is an autoimmune condition where antibodies form against the acetylcholine receptors at the neuromuscular junction, eventually causing damage to the motor end plate." | 1.46 | Myasthenia Gravis and Its Aeromedical Implications. ( Jagathesan, T; O'Brien, MD, 2017) |
| " The MG foundation of America (MGFA) classification, MGFA post-intervention status, dosage of prednisolone and pyridostigmine, and anti-acetylcholine receptor antibody titers were evaluated." | 1.42 | Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. ( Himuro, K; Kanai, T; Kawaguchi, N; Kuwabara, S; Oda, F; Uzawa, A; Yoshida, S; Yoshino, I, 2015) |
| "Myasthenia gravis is a chronic autoimmune disease of neuromuscular transmission resulting in fatigable skeletal muscle weakness." | 1.42 | New diagnosis myasthenia gravis and preeclampsia in late pregnancy. ( Balson, IF; Dennis, AT; Ozcan, J, 2015) |
| "A 64-year-old man presented with diplopia, muscle weakness, a pulmonary nodule and mediastinal widening on a chest radiograph." | 1.42 | Lung cancer associated with seronegative myasthenia gravis. ( Abe, T; Aoki, T; Asano, K; Hayama, N; Horio, Y; Inomoto, C; Murata, N; Nagata, E; Niimi, K; Oguma, T; Sato, M; Takiguchi, H; Takizawa, S; Tanaka, J; Tomomatsu, H; Tomomatsu, K; Urano, T, 2015) |
| "A 58-year-old man presented with diplopia and partial ptosis for 10 years." | 1.40 | "Why do I always see double?" A misdiagnosed case of ocular myasthenia gravis for 10 years. ( Thanigasalam, T; Ting, HS; Yashodhara, BM; Yousuf, UA, 2014) |
| "The aim of this study was to delineate the status of oral corticosteroid therapy in myasthenia gravis (MG), and to elucidate the effectiveness of oral corticosteroids according to dosing regimen." | 1.39 | [Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis]. ( Imai, T, 2013) |
| "Whereas hypothyroidism was effectively controlled with levothyroxine, his subsequent response to thymectomy, prednisolone and cholinesterase inhibitors confirmed the diagnosis of generalized myasthenia gravis." | 1.36 | Pseudo-internuclear ophthalmoplegia as a sign of overlapping myasthenia gravis in a patient with 'intractable' hypothyroidism. ( Kurokawa, K; Sugiura, T; Yamazaki, Y, 2010) |
| "Myasthenia gravis affecting one or a combination of the extraocular muscles without ptosis is less common; however, cases such as bilateral internuclear ophthalmoplegia without ptosis have been described in the literature." | 1.35 | Decompensating esophoria as the presenting feature of myasthenia gravis. ( Arblaster, GE; Pepper, IM; Shipman, TL, 2009) |
| " However, the symptoms were aggravated when the prednisolone dosage was reduced, and the titer of anti-MuSK antibody rose at the same time." | 1.34 | [Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report]. ( Kawajiri, M; Kohara, K; Miki, T; Nakahama, Y; Ochi, M; Ohta, K, 2007) |
| "Polymyositis was diagnosed by muscle biopsy which showed infiltration of lymphocytes in the endomysium and around non-necrotic muscle fibers." | 1.34 | [Concurrence of myasthenia gravis, polymyositis, thyroiditis and eosinophilia in a patient with type B1 thymoma]. ( Inoue, M; Kanda, M; Kojima, Y; Makino, F; Satoi, H; Shibasaki, H; Shinde, A, 2007) |
| "Tacrolimus is a new immunosuppressive agent acting through the selective inhibition of helper-T-cell activation that can be reduced dosage of steroids and can maintain remission of myasthenia gravis with invasive thymoma." | 1.33 | Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy. ( Deguchi, K; Ikeda, K; Kuriyama, S; Sasaki, I; Shimamura, M; Takeuchi, H; Touge, T; Tsukaguchi, M; Urai, Y, 2005) |
| "His thymoma was not removed completely due to adhesion with other organs." | 1.33 | [A case of myasthenia gravis appearing after thymomectomy: with histopathological investigation]. ( Kusunoki, S; Miyamoto, K; Sato, T; Shioyama, M; Sunayama, M, 2006) |
| " Mycophenolate mofetil was used in combination with cyclosporine and prednisone and allowed for significant reductions in dosage of these immunosuppressants." | 1.31 | Treatment of myasthenia gravis with mycophenolate mofetil: a case report. ( Meriggioli, MN; Rowin, J, 2000) |
| "Oral prednisolone therapy was effective." | 1.31 | [A case of myasthenia gravis following sarcoidosis and Hashimoto's thyroiditis]. ( Ibi, T; Nakao, N; Nishida, H; Sahashi, K; Tanaka, Y, 2000) |
| "The combination of idiopathic thrombocytopenic purpura (ITP) and myasthenia gravis (MG) has been reported infrequently." | 1.31 | A case with myasthenia gravis (MG) emerging after splenectomy for idiopathic thrombocytopenic purpura (ITP): possible effects of thymectomy on autoantibodies. ( Matsuno, S; Shoji, S; Tamaoka, A; Watanabe, M; Yoshizawa, K, 2000) |
| "Ocular myasthenia gravis is a subtype of myasthenia gravis that causes relatively mild disability, but may convert into severe generalised muscle weakness." | 1.30 | Ocular myasthenia gravis: response to long-term immunosuppressive treatment. ( Dichgans, J; Herzau, V; Melms, A; Schepelmann, K; Sigg, B; Sommer, N; Weller, M, 1997) |
| "Several treatments for alopecia areata including administration of systemic prednisolone were attempted, but loss of hair on the scalp progressed." | 1.30 | Alopecia areata associated with myasthenia gravis and thymoma: a case of alopecia with marked improvement following thymectomy and high level prednisolone administration. ( Hatamochi, A; Kamada, N; Shinkai, H, 1997) |
| "A 37-year-old Japanese man with chronic myeloid leukemia (CML) developed myasthenia gravis 29 months after bone marrow transplantation (BMT) from an HLA one locus-mismatched brother." | 1.29 | Myasthenia gravis after allogeneic bone marrow transplantation. ( Gondo, H; Harada, M; Nakamura, M; Niho, Y; Okamura, S; Otsuka, T; Sano, T; Shimoda, K, 1994) |
| "Myasthenia gravis is a specific autoimmune disease characterised by weakness and fatigue." | 1.29 | Breathing pattern and central ventilatory drive in mild and moderate generalised myasthenia gravis. ( Alvarez-Sala, R; Díaz Lobato, S; Díez Tejedor, E; García Río, F; Pino, JM; Prados, C; Villamor, J, 1994) |
| "We carried out lymphocytapheresis (LCP) in combination with the administration of immunosuppressive drugs in patients with myasthenia gravis (MG), who were resistant to conventional immunosuppressive therapy, and examined its efficacy and effects on peripheral blood lymphocyte subsets." | 1.29 | Lymphocytapheresis in combination with immunosuppressive drugs for refractory myasthenia gravis: two-color flow cytometric analysis of changes in peripheral blood lymphocyte subsets. ( Furutama, D; Makino, S; Nakajima, H; Ohsawa, N; Shinoda, K, 1995) |
| "We report a 20-year-old female with generalized myasthenia gravis (MG) who developed atonic urinary bladder and accommodative insufficiency." | 1.29 | Seronegative myasthenia gravis associated with atonic urinary bladder and accommodative insufficiency. ( Enoki, M; Kuroda, Y; Matsui, M; Matsui, Y; Ohta, M; Oono, S; Suenaga, A, 1995) |
| " Through data of these cases, it is recommended that the maximum dosage is to be continued for as long as 2 to 19 weeks with average 7 weeks." | 1.28 | [Myasthenia gravis and steroid therapy]. ( Araki, Y; Kinoshita, M; Nemoto, H; Niizuma, M; Wakata, N, 1992) |
| "The thymoma is sensitive to corticosteroids, which can effectively reduce it." | 1.28 | [A case of a small thymoma associated with myasthenia gravis in which the tumor was reduced by corticosteroid therapy]. ( Hashimoto, T; Masaoka, A; Mizuno, T; Niwa, H; Yamakawa, Y, 1992) |
| "A patient developed respiratory failure after surgical removal of a recurrent thymoma, which necessitated removal of part of the diaphragm." | 1.28 | Unsuspected myasthenia gravis presenting as respiratory failure. ( Green, M; Laroche, C; Mier, A, 1990) |
| "A total of 149 patients with autoimmune thyroiditis, endocrine ophthalmopathy, myasthenia and bronchial asthma were examined." | 1.27 | [Status of the hypophysis-adrenal cortex system during treatment with glucocorticoids by the method of intermittent (every other day) administration]. ( Beĭsugurov, MSh; Ibragimova, GV; Shmushkovich, BI; Zefirova, GS, 1986) |
| " The treatment with ciclosporin has been continued in all 6 patients, but the dosage has been reduced to 5 mg/kg/day." | 1.27 | Myasthenia gravis treated with ciclosporin. ( Gjerstad, L; Nyberg-Hansen, R, 1988) |
| " These results suggested that prednisolone treatment with a smaller dosage as well as with the higher dosage resulted in a carbohydrate intolerance, the main cause of which is located in a postreceptor step (or steps) of insulin action." | 1.27 | Erythrocyte insulin receptor and glucose tolerance test in children treated with prednisolone. ( Fujimoto, S; Kan, H; Matsuda, I, 1985) |
| " Three poorly controlled patients were studied on a high-dose alternate-day steroid regimen, and a marked decrease in pyridostigmine bioavailability on the same dose of drug was observed in all three." | 1.26 | Plasma pyridostigmine levels in myasthenia gravis. ( De Silva, P; Havard, CW; White, MC, 1981) |
| "Anti-acetylcholine receptor antibody titres have been monitored in the sera of 19 myasthenic patients treated with plasma exchange combined with a three month period of immunosuppressive therapy." | 1.26 | Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy. ( Behan, PO; Carter, B; Harrison, R; Lunt, GG; Simpson, JA, 1980) |
| "Twenty-one patients with myasthenia gravis underwent a course of plasma exchange combined with immunosuppressive therapy." | 1.26 | Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. ( Allan, TL; Behan, PO; Burnett, AK; Haase, G; Shakir, RA; Simpson, JA, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (22.62) | 18.7374 |
| 1990's | 39 (15.48) | 18.2507 |
| 2000's | 70 (27.78) | 29.6817 |
| 2010's | 62 (24.60) | 24.3611 |
| 2020's | 24 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Li, F | 1 |
| Zhu, H | 1 |
| Yu, H | 1 |
| Wang, T | 1 |
| Yan, X | 1 |
| Sakae, H | 1 |
| Mawatari, S | 1 |
| Oda, K | 1 |
| Tabu, K | 1 |
| Kumagai, K | 1 |
| Mizuno, K | 1 |
| Nozuma, S | 1 |
| Kitazono, I | 1 |
| Kanmura, S | 1 |
| Ido, A | 1 |
| Wu, H | 1 |
| Chen, L | 1 |
| Zhou, X | 1 |
| Wu, Y | 1 |
| Yan, Y | 1 |
| Zhu, Y | 1 |
| Zhao, C | 1 |
| Xue, Q | 1 |
| Yoshikawa, H | 5 |
| Adachi, Y | 1 |
| Nakamura, Y | 1 |
| Kuriyama, N | 1 |
| Murai, H | 9 |
| Nomura, Y | 1 |
| Sakai, Y | 1 |
| Iwasa, K | 3 |
| Furukawa, Y | 2 |
| Kuwabara, S | 4 |
| Matsui, M | 3 |
| Abdelhamid, NS | 1 |
| Farid, NF | 1 |
| Anwar, BH | 1 |
| Magdy, MA | 1 |
| Sugimoto, T | 3 |
| Yamawaki, T | 3 |
| Naito, H | 3 |
| Ohno, N | 3 |
| Giga, M | 3 |
| Kono, T | 3 |
| Ochi, K | 3 |
| Kohriyama, T | 3 |
| Nomura, E | 3 |
| Maruyama, H | 3 |
| Uzawa, A | 6 |
| Ozawa, Y | 2 |
| Yasuda, M | 1 |
| Onishi, Y | 1 |
| Akamine, H | 1 |
| Krishna, L | 1 |
| Abdul Jalil, NF | 1 |
| Lott, PW | 1 |
| Singh, S | 1 |
| Choo, MM | 1 |
| Rejdak, K | 1 |
| Szklener, S | 1 |
| Korchut, A | 1 |
| Baranowski, D | 1 |
| Paranavitane, S | 1 |
| Handagala, S | 1 |
| De Silva, R | 1 |
| Chang, T | 1 |
| Saluja, G | 1 |
| Samdani, A | 1 |
| Bhatia, P | 1 |
| Fukazawa, R | 1 |
| Takezawa, H | 1 |
| Tsuji, Y | 1 |
| Noto, Y | 1 |
| Banba, M | 1 |
| Fujii, A | 1 |
| Oliveira, R | 1 |
| Landeiro, L | 1 |
| Lauterbach, M | 1 |
| Finsterer, J | 1 |
| Scorza, CA | 1 |
| Fiorini, AC | 1 |
| Scorza, FA | 1 |
| Lin, CY | 1 |
| Liu, WC | 1 |
| Chiang, MH | 1 |
| Tsai, IT | 1 |
| Chen, JY | 1 |
| Cheng, WJ | 1 |
| Ho, CN | 1 |
| Liao, SW | 1 |
| Chu, CC | 1 |
| Sun, CK | 1 |
| Hung, KC | 1 |
| Chakraborty, A | 1 |
| Jacob, J | 1 |
| Yanagihashi, M | 1 |
| Okamoto, R | 1 |
| Morioka, H | 1 |
| Sawada, M | 1 |
| Matsumoto, S | 1 |
| Ikeda, T | 1 |
| Kano, O | 1 |
| Matsumoto, Y | 1 |
| Shima, K | 2 |
| Yamaguchi, K | 1 |
| Shimizu, A | 1 |
| Yoshizumi, K | 1 |
| Kimura, T | 1 |
| Ukon, S | 1 |
| Watanabe, S | 3 |
| Kasama, S | 1 |
| Takeda, M | 1 |
| Katsuki, M | 1 |
| Sugahara, H | 1 |
| Kojima, Y | 2 |
| Yamashita, K | 1 |
| Moriuchi, H | 1 |
| Kubota, T | 1 |
| Masuda, M | 7 |
| Irikura, M | 1 |
| Wang, Y | 1 |
| Zhao, N | 1 |
| Yang, J | 1 |
| Wen, Y | 1 |
| Sharshar, T | 2 |
| Porcher, R | 1 |
| Demeret, S | 1 |
| Tranchant, C | 1 |
| Gueguen, A | 1 |
| Eymard, B | 1 |
| Nadaj-Pakleza, A | 1 |
| Spinazzi, M | 1 |
| Grimaldi, L | 1 |
| Birnbaum, S | 1 |
| Friedman, D | 1 |
| Clair, B | 1 |
| Menon, SMR | 1 |
| Mokkath, NR | 1 |
| Siriratnam, P | 1 |
| Zhang, W | 1 |
| Faragher, M | 1 |
| Campion, T | 1 |
| Maity, A | 1 |
| Ali, S | 1 |
| Richards, P | 1 |
| Adams, A | 1 |
| Karimi, N | 1 |
| Okhovat, AA | 1 |
| Ziaadini, B | 1 |
| Haghi Ashtiani, B | 1 |
| Nafissi, S | 1 |
| Fatehi, F | 1 |
| Hasegawa, Y | 1 |
| Kawai, S | 1 |
| Ota, T | 1 |
| Tsukuda, H | 1 |
| Fukuoka, M | 1 |
| Khan, MS | 1 |
| Habib, A | 1 |
| Basit, I | 1 |
| Konoeda, F | 1 |
| Suzuki, S | 8 |
| Nishimoto, Y | 1 |
| Hoshino, H | 1 |
| Takagi, M | 1 |
| Ahn, SW | 1 |
| Joo, IS | 1 |
| Kim, BJ | 2 |
| Sung, JJ | 1 |
| Kang, SY | 1 |
| Oh, J | 1 |
| Minn, YK | 1 |
| Suh, BC | 1 |
| Oh, SY | 1 |
| Hong, YH | 1 |
| Nam, TS | 1 |
| Seok, JI | 1 |
| Park, YE | 1 |
| Shin, HY | 1 |
| Cho, EB | 1 |
| Shin, JY | 1 |
| Seok, HY | 1 |
| Park, JS | 1 |
| Min, JH | 1 |
| Seok, JM | 1 |
| Imai, T | 7 |
| Utsugisawa, K | 9 |
| Tsuda, E | 5 |
| Nagane, Y | 10 |
| Suzuki, Y | 4 |
| Minami, N | 4 |
| Kawaguchi, N | 7 |
| Konno, S | 8 |
| Suzuki, H | 4 |
| Akaishi, T | 2 |
| Aoki, M | 3 |
| Motomura, M | 7 |
| Dube, M | 1 |
| Sodani, A | 1 |
| Chouksey, D | 1 |
| Oono, M | 1 |
| Fujita, Y | 2 |
| Uchida, N | 1 |
| Kawai, U | 1 |
| Fujita-Nakata, M | 1 |
| Nakanishi, M | 1 |
| Sanada, M | 1 |
| Nagayama, S | 1 |
| Kopp, CR | 1 |
| Jandial, A | 1 |
| Mishra, K | 1 |
| Sandal, R | 1 |
| Malhotra, P | 1 |
| Omata, T | 1 |
| Fukui, K | 1 |
| Kodama, K | 1 |
| Watanabe, Y | 1 |
| Aoyama, H | 1 |
| Fujii, K | 1 |
| Shimojo, N | 1 |
| Chandra, A | 1 |
| Pant, B | 1 |
| Bopeththa, BVKM | 1 |
| Hewavithana, PB | 1 |
| Hewapathirana, HLI | 1 |
| Ralapanawa, U | 1 |
| Kavanagh, C | 1 |
| Lilleker, J | 1 |
| MacDonagh, R | 1 |
| Isami, A | 1 |
| Uchiyama, A | 1 |
| Shimaoka, Y | 1 |
| Kawachi, I | 1 |
| Fujita, N | 1 |
| Noda, T | 1 |
| Kageyama, H | 1 |
| Miura, M | 1 |
| Tamura, T | 2 |
| Ito, H | 1 |
| Hill, PB | 1 |
| Brain, P | 1 |
| Collins, D | 1 |
| Fearnside, S | 1 |
| Olivry, T | 1 |
| Nakane, S | 3 |
| Yamada, Y | 1 |
| Yoshida, S | 2 |
| Tagawa, T | 1 |
| Iwata, T | 1 |
| Mizobuchi, T | 1 |
| Yoshino, I | 2 |
| Horai, Y | 1 |
| Honda, M | 1 |
| Nishino, A | 1 |
| Nakashima, Y | 1 |
| Suzuki, T | 1 |
| Kawashiri, SY | 1 |
| Ichinose, K | 1 |
| Tamai, M | 1 |
| Nakamura, H | 1 |
| Origuchi, T | 1 |
| Kawakami, A | 1 |
| Yousuf, UA | 1 |
| Yashodhara, BM | 1 |
| Thanigasalam, T | 1 |
| Ting, HS | 1 |
| Saraei, M | 1 |
| Hosseinbigi, B | 1 |
| Shahnazi, M | 1 |
| Bijani, B | 1 |
| Oji, S | 1 |
| Suzuki, N | 4 |
| Zouvelou, V | 1 |
| Vasiliki, Z | 1 |
| Velonakis, G | 1 |
| Georgios, V | 1 |
| Rontogianni, D | 1 |
| Dimitra, R | 1 |
| Zisis, C | 1 |
| Charalambos, Z | 1 |
| Fujihara, K | 1 |
| Court, JH | 1 |
| Janicek, D | 1 |
| Kanai, T | 3 |
| Himuro, K | 2 |
| Oda, F | 2 |
| Ozcan, J | 1 |
| Balson, IF | 1 |
| Dennis, AT | 1 |
| Niimi, K | 1 |
| Nagata, E | 1 |
| Murata, N | 1 |
| Sato, M | 2 |
| Tanaka, J | 1 |
| Horio, Y | 1 |
| Takiguchi, H | 1 |
| Tomomatsu, H | 1 |
| Tomomatsu, K | 1 |
| Hayama, N | 1 |
| Oguma, T | 1 |
| Aoki, T | 1 |
| Urano, T | 1 |
| Abe, T | 2 |
| Inomoto, C | 1 |
| Takizawa, S | 1 |
| Asano, K | 1 |
| Furuta, N | 1 |
| Ishizawa, K | 1 |
| Shibata, M | 1 |
| Tsukagoshi, S | 1 |
| Nagamine, S | 1 |
| Makioka, K | 1 |
| Ikeda, M | 1 |
| Yoshimura, S | 1 |
| Okamoto, K | 1 |
| Ikeda, Y | 1 |
| Kitamura, E | 1 |
| Takiyama, Y | 1 |
| Nakamura, M | 2 |
| Iizuka, T | 1 |
| Nishiyama, K | 1 |
| Hirata, Y | 1 |
| Inoue, M | 3 |
| Nabatame, S | 1 |
| Okumura, M | 1 |
| Ozono, K | 1 |
| Jagathesan, T | 1 |
| O'Brien, MD | 1 |
| Yamamoto, D | 1 |
| Sanders, DB | 3 |
| Siddiqi, ZA | 1 |
| Prasad, KP | 1 |
| Alahakoon, DG | 1 |
| Vidanagama, U | 1 |
| Tanaka, S | 3 |
| Nakajima, K | 1 |
| Ido, N | 1 |
| Ohtsuka, T | 1 |
| Nishida, M | 1 |
| Utsumi, H | 1 |
| Hirano, T | 2 |
| Stieglbauer, K | 1 |
| Topakian, R | 1 |
| Schäffer, V | 1 |
| Aichner, FT | 1 |
| Arblaster, GE | 1 |
| Shipman, TL | 1 |
| Pepper, IM | 1 |
| Rózsa, C | 1 |
| Mikor, A | 1 |
| Kasa, K | 1 |
| Illes, Z | 1 |
| Komoly, S | 1 |
| Luther, C | 1 |
| Adamopoulou, E | 1 |
| Stoeckle, C | 1 |
| Brucklacher-Waldert, V | 1 |
| Rosenkranz, D | 1 |
| Stoltze, L | 1 |
| Lauer, S | 1 |
| Poeschel, S | 1 |
| Melms, A | 2 |
| Tolosa, E | 1 |
| Angelucci, E | 1 |
| Cesarini, M | 1 |
| Vernia, P | 1 |
| Niiyama, S | 1 |
| Amoh, Y | 1 |
| Suzuki, K | 1 |
| Wada, T | 1 |
| Katsuoka, K | 1 |
| Yanagawa, Y | 1 |
| Hongo, Y | 1 |
| Shiozaki, H | 1 |
| Kamakura, K | 1 |
| Sonoo, M | 1 |
| Seker, M | 1 |
| Gozu, HI | 1 |
| Oven Ustaalioğlu, BB | 1 |
| Sonmez, B | 1 |
| Erkal, FY | 1 |
| Kocak, M | 1 |
| Barisik, NO | 1 |
| Orbay, E | 1 |
| Sargin, M | 1 |
| Sargin, H | 1 |
| Boru, UT | 1 |
| Yaylaci, M | 1 |
| Ichijo, T | 1 |
| Murata, M | 1 |
| Toda, T | 1 |
| Nakazora, H | 2 |
| Nomoto, N | 4 |
| Sugimoto, H | 5 |
| Nemoto, H | 4 |
| Kurihara, T | 3 |
| Wakata, N | 10 |
| Fujioka, T | 1 |
| Yamazaki, Y | 1 |
| Sugiura, T | 1 |
| Kurokawa, K | 1 |
| Sugawara, M | 1 |
| Wada, C | 2 |
| Okawa, S | 1 |
| Kobayashi, M | 3 |
| Abe, E | 1 |
| Obara, K | 2 |
| Kamada, S | 1 |
| Ohnishi, H | 1 |
| Toyoshima, I | 2 |
| Miura, S | 1 |
| Azuma, K | 1 |
| Yamada, K | 1 |
| Takamori, S | 1 |
| Kawahara, A | 1 |
| Noda, K | 1 |
| Ayabe, M | 1 |
| Kage, M | 1 |
| Aizawa, H | 2 |
| Taniwaki, T | 1 |
| Fujiki, N | 1 |
| Doi, S | 1 |
| Niino, M | 1 |
| Kikuchi, S | 1 |
| Sasaki, H | 1 |
| Sidnev, DV | 1 |
| Sanadze, AG | 2 |
| Dedaev, SI | 1 |
| Karganov, MIu | 1 |
| Alchinova, IB | 1 |
| Ebert, S | 1 |
| Schweiger, KP | 1 |
| Nau, R | 2 |
| Takamori, M | 3 |
| Kiuchi, T | 1 |
| Saida, T | 1 |
| Kataoka, H | 1 |
| Kiriyama, T | 1 |
| Ueno, S | 1 |
| Çakır, ED | 1 |
| Özdemir, Ö | 1 |
| Eren, E | 1 |
| Sağlam, H | 1 |
| Okan, M | 1 |
| Tarım, ÖF | 1 |
| Koinuma, T | 1 |
| Nunomiya, S | 1 |
| Wada, M | 1 |
| Misawa, K | 1 |
| Koyama, K | 1 |
| Rehman, HU | 1 |
| Rajasekharan, C | 1 |
| Anishkumar, V | 1 |
| Suresh, MK | 1 |
| Yoshida, Y | 1 |
| Ueda, R | 1 |
| Murakawa, T | 1 |
| Ota, S | 1 |
| Nakajima, J | 1 |
| Nakamura, S | 1 |
| Kaneko, S | 1 |
| Shinde, A | 2 |
| Morita, J | 1 |
| Fujita, K | 1 |
| Nakano, S | 1 |
| Kusaka, H | 2 |
| Zach, H | 1 |
| Cetin, H | 1 |
| Hilger, E | 1 |
| Paul, A | 1 |
| Wuschitz, B | 1 |
| Jung, R | 1 |
| Auff, E | 1 |
| Zimprich, F | 1 |
| Spillane, J | 1 |
| Hirsch, NP | 1 |
| Kullmann, DM | 1 |
| Taylor, C | 1 |
| Howard, RS | 1 |
| Haas, M | 1 |
| Mayr, N | 1 |
| Zeitlhofer, J | 1 |
| Goldammer, A | 1 |
| Derfler, K | 1 |
| Rastenyte, D | 1 |
| Vaitkus, A | 1 |
| Neverauskas, R | 1 |
| Pauza, V | 1 |
| Mabuchi, K | 1 |
| Yasukawa, Y | 1 |
| Yamada, M | 2 |
| Kaji, M | 1 |
| Sato, Y | 3 |
| Kunoh, H | 1 |
| Watanabe, A | 1 |
| Oizumi, K | 1 |
| Iguchi, H | 2 |
| Kameyama, K | 1 |
| Noguchi, Y | 1 |
| Matsumoto, T | 1 |
| Takenawa, H | 1 |
| Fujigasaki, H | 1 |
| Kanda, T | 1 |
| Mizusawa, H | 1 |
| Saito, T | 2 |
| Oka, K | 1 |
| Hayashi, N | 1 |
| Araki, Y | 4 |
| Nakazato, A | 3 |
| Endo, S | 1 |
| Yamaguchi, T | 1 |
| Saito, N | 1 |
| Otani, S | 1 |
| Hasegawa, T | 1 |
| Sohara, Y | 1 |
| Shimojima, Y | 2 |
| Gono, T | 2 |
| Yamamoto, K | 1 |
| Hoshi, K | 1 |
| Matsuda, M | 2 |
| Yoshida, K | 1 |
| Ikeda, S | 2 |
| Richaud-Patin, Y | 1 |
| Vega-Boada, F | 1 |
| Vidaller, A | 1 |
| Llorente, L | 1 |
| Tanaka, K | 3 |
| Suzuki, E | 1 |
| Kotoh, K | 1 |
| Fukahara, K | 1 |
| Doi, T | 1 |
| Misaki, T | 1 |
| Tsukaguchi, M | 1 |
| Shimamura, M | 1 |
| Ikeda, K | 1 |
| Urai, Y | 1 |
| Sasaki, I | 1 |
| Deguchi, K | 1 |
| Touge, T | 1 |
| Takeuchi, H | 1 |
| Kuriyama, S | 1 |
| Ponseti, JM | 1 |
| Azem, J | 1 |
| Fort, JM | 1 |
| Codina, A | 1 |
| Montoro, JB | 1 |
| Armengol, M | 1 |
| Masaki, K | 1 |
| Shiga, K | 1 |
| Mizuno, T | 2 |
| Ijichi, T | 1 |
| Nakagawa, M | 1 |
| Bankar, RN | 1 |
| Köhnke, A | 1 |
| Ishii, W | 1 |
| Tokuda, T | 1 |
| Hain, B | 2 |
| Jordan, K | 1 |
| Deschauer, M | 1 |
| Zierz, S | 2 |
| Bau, V | 1 |
| Hanisch, F | 1 |
| Bennett, DL | 1 |
| Mills, KR | 1 |
| Riordan-Eva, P | 1 |
| Barnes, PR | 1 |
| Rose, MR | 1 |
| Prakash, KM | 1 |
| Ratnagopal, P | 1 |
| Puvanendran, K | 1 |
| Lo, YL | 1 |
| Tada, M | 2 |
| Shimohata, T | 1 |
| Oyake, M | 1 |
| Igarashi, S | 1 |
| Onodera, O | 1 |
| Naruse, S | 1 |
| Tsuji, S | 1 |
| Nishizawa, M | 2 |
| Iwadate, H | 1 |
| Kobayashi, H | 1 |
| Shio, K | 1 |
| Noguchi, E | 1 |
| Watanabe, K | 1 |
| Sasajima, T | 1 |
| Sekine, H | 1 |
| Watanabe, H | 1 |
| Ohira, H | 1 |
| Sekine, Y | 1 |
| Hamada, C | 1 |
| Sekiguchi, H | 1 |
| Yasufuku, K | 1 |
| Iyoda, A | 1 |
| Shibuya, K | 1 |
| Fujisawa, T | 1 |
| de Carvalho, M | 1 |
| Geraldes, R | 1 |
| Sunayama, M | 1 |
| Miyamoto, K | 1 |
| Shioyama, M | 1 |
| Sato, T | 4 |
| Kusunoki, S | 1 |
| Alevizos, B | 1 |
| Gatzonis, S | 1 |
| Anagnostara, Ch | 1 |
| Fujishima, N | 1 |
| Hirokawa, M | 1 |
| Fujishima, M | 1 |
| Sawada, K | 1 |
| Lim, AK | 1 |
| Donnan, G | 1 |
| Chambers, B | 1 |
| Ierino, FL | 1 |
| Hara, K | 1 |
| Mashima, T | 1 |
| Matsuda, A | 1 |
| Tomita, M | 1 |
| Shiraishi, H | 1 |
| Iseki, K | 1 |
| Mezaki, T | 1 |
| Kawamoto, Y | 1 |
| Tomimoto, H | 1 |
| Fukuyama, H | 1 |
| Shibasaki, H | 2 |
| Hamizah, R | 1 |
| Norlinah, MI | 1 |
| Tan, HJ | 1 |
| Soehardy, Z | 1 |
| Halim, AG | 1 |
| Rohana, AG | 1 |
| Hamidon, BB | 1 |
| Kong, NC | 1 |
| Raymond, AA | 1 |
| Nakahama, Y | 1 |
| Kawajiri, M | 1 |
| Ochi, M | 1 |
| Kohara, K | 1 |
| Ohta, K | 1 |
| Miki, T | 1 |
| Satoi, H | 1 |
| Makino, F | 1 |
| Kanda, M | 1 |
| Hart, IK | 2 |
| Sathasivam, S | 1 |
| Hilton-Jones, D | 1 |
| Brostoff, JM | 1 |
| Dahdaleh, D | 1 |
| Birns, J | 1 |
| Fujii, Y | 1 |
| Kaneda, H | 1 |
| Saito, Y | 2 |
| Maniwa, T | 1 |
| Minami, K | 1 |
| Imamura, H | 1 |
| Nagaishi, A | 1 |
| Yukitake, M | 1 |
| Kuroda, Y | 2 |
| Ingram, DA | 1 |
| Davis, GR | 1 |
| Schwartz, MS | 1 |
| Traub, M | 1 |
| Newland, AC | 1 |
| Swash, M | 1 |
| Gajdos, P | 1 |
| Simon, N | 1 |
| de Rohan-Chabot, P | 1 |
| Raphael, JC | 1 |
| Goulon, M | 1 |
| Milner-Brown, HS | 1 |
| Miller, RG | 1 |
| Rasstrigin, NN | 1 |
| Abubakirova, AM | 1 |
| Dizna, SN | 1 |
| Sakashita, I | 1 |
| Fukuoka, T | 1 |
| Nakamura, N | 1 |
| Osame, M | 1 |
| Igata, A | 1 |
| Conti-Tronconi, BM | 1 |
| Scotti, A | 1 |
| Sghirlanzoni, A | 1 |
| Clementi, F | 1 |
| Yamaguchi, Y | 3 |
| Baba, M | 3 |
| Shoman, S | 1 |
| Kawano, H | 1 |
| Ito, N | 2 |
| Mozai, T | 1 |
| Masui, Y | 1 |
| Hirayama, K | 1 |
| Kuroda, N | 1 |
| Yoshimatsu, H | 1 |
| Ishikura, Y | 1 |
| Murakami, M | 1 |
| Kawahara, H | 1 |
| Nagata, M | 1 |
| White, MC | 1 |
| De Silva, P | 1 |
| Havard, CW | 2 |
| Pal'tsev, MA | 1 |
| Popova, LM | 1 |
| Carter, B | 1 |
| Harrison, R | 1 |
| Lunt, GG | 1 |
| Behan, PO | 2 |
| Simpson, JA | 2 |
| Barone, DA | 1 |
| Lambert, DH | 1 |
| Poser, CM | 1 |
| Yahikozawa, H | 1 |
| Koh, CS | 1 |
| Inoue, A | 1 |
| Hashimoto, T | 2 |
| Yanagisawa, N | 1 |
| Sumiyoshi, S | 1 |
| Tagaya, N | 1 |
| Okada, S | 1 |
| Kinoshita, M | 5 |
| Okada, T | 1 |
| Kawamura, T | 1 |
| Toshima, R | 1 |
| Sakai, O | 1 |
| Shimoda, K | 1 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Sano, T | 1 |
| Otsuka, T | 1 |
| Okamura, S | 1 |
| Niho, Y | 1 |
| Moore, CE | 1 |
| Wheatley, EC | 1 |
| Jefferson, MF | 1 |
| Shepherd, DI | 1 |
| García Río, F | 1 |
| Prados, C | 1 |
| Díez Tejedor, E | 1 |
| Díaz Lobato, S | 1 |
| Alvarez-Sala, R | 1 |
| Villamor, J | 1 |
| Pino, JM | 1 |
| Seto, M | 1 |
| Takeo, G | 1 |
| Yoshimura, T | 1 |
| Tsujihata, M | 2 |
| Nagataki, S | 2 |
| Kao, KP | 1 |
| Kwan, SY | 1 |
| Lin, KP | 1 |
| Chang, YC | 1 |
| Furutama, D | 1 |
| Nakajima, H | 1 |
| Shinoda, K | 1 |
| Makino, S | 1 |
| Ohsawa, N | 1 |
| Enoki, M | 1 |
| Matsui, Y | 1 |
| Oono, S | 1 |
| Ohta, M | 2 |
| Suenaga, A | 1 |
| Ishida, Y | 1 |
| Hayashi, M | 1 |
| Higaki, A | 1 |
| Matsumoto, K | 1 |
| Iikura, Y | 1 |
| Ishikawa, J | 1 |
| Kida, K | 1 |
| Glennerster, A | 1 |
| Palace, J | 2 |
| Warburton, D | 1 |
| Oxbury, S | 1 |
| Newsom-Davis, J | 2 |
| Saeki, S | 1 |
| Fukusako, T | 1 |
| Negoro, K | 1 |
| Nogaki, H | 1 |
| Morimatsu, M | 1 |
| Sommer, N | 1 |
| Sigg, B | 1 |
| Weller, M | 1 |
| Schepelmann, K | 1 |
| Herzau, V | 1 |
| Dichgans, J | 1 |
| Kubota, A | 1 |
| Komiyama, A | 1 |
| Hasegawa, O | 1 |
| Berrouschot, J | 1 |
| Baumann, I | 1 |
| Kalischewski, P | 1 |
| Sterker, M | 1 |
| Schneider, D | 1 |
| Tumani, H | 1 |
| George, A | 1 |
| Lindner, A | 1 |
| Schalke, B | 1 |
| Toyka, KV | 2 |
| Kamada, N | 1 |
| Hatamochi, A | 1 |
| Shinkai, H | 1 |
| Lecky, B | 1 |
| Takahashi, T | 2 |
| Kuwao, S | 1 |
| Katagiri, H | 1 |
| Kakita, A | 1 |
| Tomida, C | 1 |
| Yamagata, K | 1 |
| Ishizu, T | 1 |
| Nakajima, M | 1 |
| Doi, M | 1 |
| Koyama, A | 1 |
| Asanuma, K | 1 |
| Saida, K | 1 |
| Konishi, T | 1 |
| Agrawal, S | 1 |
| Datta, NR | 1 |
| Mishra, SK | 1 |
| Kumar, S | 1 |
| Tandon, V | 1 |
| Ayyagari, S | 1 |
| Agarwal, A | 1 |
| Romanchishen, AF | 1 |
| Chukhlovina, ML | 1 |
| Kolosiuk, VA | 1 |
| Meriggioli, MN | 1 |
| Rowin, J | 1 |
| Takahashi, K | 1 |
| Inoue, Y | 1 |
| Matsuda, O | 1 |
| Takemura, T | 1 |
| Yoshimura, A | 1 |
| Sasakura, Y | 1 |
| Kumasaka, S | 1 |
| Shindo, J | 1 |
| Nishida, H | 1 |
| Tanaka, Y | 1 |
| Nakao, N | 1 |
| Ibi, T | 1 |
| Sahashi, K | 1 |
| Sharp, HR | 1 |
| Degrip, A | 1 |
| Mitchell, DB | 1 |
| Heller, A | 1 |
| Shinomiya, N | 1 |
| Smith, GD | 1 |
| Stevens, DL | 1 |
| Fuller, GN | 1 |
| Saito, R | 1 |
| Matsuno, S | 1 |
| Tamaoka, A | 1 |
| Yoshizawa, K | 1 |
| Watanabe, M | 1 |
| Shoji, S | 2 |
| Kira, J | 1 |
| Huh, WK | 1 |
| Tada, J | 1 |
| Fujimoto, W | 1 |
| Toi, Y | 1 |
| Arakawa, K | 1 |
| Arata, J | 1 |
| Morita, H | 1 |
| Hamada, H | 1 |
| Roberts, ME | 1 |
| Steiger, MJ | 1 |
| Kimura, K | 1 |
| Hasegawa, K | 1 |
| Fujiwara, K | 1 |
| Nakagawa, K | 1 |
| Yasumitsu, T | 1 |
| Delaney, Y | 1 |
| Khooshabeh, R | 1 |
| Benjamin, L | 1 |
| Ratanakorn, D | 1 |
| Vejjajiva, A | 1 |
| Shakir, RA | 1 |
| Burnett, AK | 1 |
| Allan, TL | 1 |
| Haase, G | 1 |
| Wolters, MJ | 1 |
| Leeuwin, RS | 2 |
| Wolters, EC | 1 |
| Kim, YI | 1 |
| Goldner, MM | 1 |
| Takatsu, M | 1 |
| Toyokura, Y | 2 |
| Dudel, J | 1 |
| Birnberger, KL | 1 |
| Schlegel, C | 1 |
| Besinger, U | 1 |
| Ota, M | 1 |
| Hayashi, K | 1 |
| Satoyoshi, E | 1 |
| Kamei, N | 1 |
| Ishizuka, H | 1 |
| Nishitani, Y | 1 |
| Kurihara, J | 1 |
| Tsunematsu, T | 1 |
| Klingler, D | 1 |
| Necek, S | 1 |
| Brücke, P | 1 |
| Johns, TR | 1 |
| Eldefrawi, ME | 1 |
| Cobb, EE | 1 |
| Dandona, P | 1 |
| Corkan, EJ | 1 |
| Sladen, GE | 1 |
| Noguchi, S | 1 |
| Ichikawa, Y | 1 |
| Nakata, Y | 1 |
| Koriyama, K | 1 |
| Komatsuda, M | 1 |
| Arimori, S | 2 |
| Chen, RC | 1 |
| Sung, SM | 1 |
| Soong, WT | 1 |
| Ryu, SJ | 1 |
| Sun, JL | 1 |
| Hung, TP | 1 |
| Gekht, VM | 1 |
| Kuzin, MI | 1 |
| Kuralsein, MG | 1 |
| Shagal, DI | 3 |
| Ouchi, M | 1 |
| Shoji, Y | 1 |
| Yoshida, I | 1 |
| Itoh, Y | 1 |
| Ohmi, M | 1 |
| Saji, K | 1 |
| Niizuma, M | 1 |
| Yamakawa, Y | 1 |
| Niwa, H | 1 |
| Masaoka, A | 1 |
| Klimova, TT | 1 |
| Skoromets, AA | 1 |
| Khliustova, OV | 1 |
| Kamolvarin, N | 1 |
| Hemachudha, T | 1 |
| Ongpipattanakul, B | 1 |
| Phanthumchinda, K | 1 |
| Sueblinvong, T | 1 |
| Shrivastava, MP | 1 |
| Datta, TK | 1 |
| Madiajagne, R | 1 |
| Vetshev, PS | 2 |
| Shkrob, OS | 2 |
| Zaĭrat'iants, OV | 1 |
| Ippolitov, IKh | 2 |
| Chilingaridi, KE | 1 |
| Kurochkin, AV | 1 |
| Kawamura, Y | 2 |
| Shin, K | 1 |
| Kobayashi, T | 1 |
| Sokolov, AL | 1 |
| Voronov, LI | 1 |
| Khodzhaev, ZSh | 1 |
| Neretin, VIa | 1 |
| Odinokova, VA | 1 |
| Kir'iakov, VA | 1 |
| Sapfirova, VA | 1 |
| Fonseca, V | 1 |
| Mamikonian, AA | 1 |
| Gekht, BM | 2 |
| Orlov, VA | 1 |
| Mier, A | 1 |
| Laroche, C | 1 |
| Green, M | 1 |
| Sato, H | 1 |
| Araki, S | 1 |
| Mariasy, Y | 1 |
| Shapiro, A | 1 |
| Mitchell, TH | 1 |
| Ivanov, IP | 1 |
| Kolomenskaia, EA | 2 |
| Iakovleva, AN | 1 |
| Zefirova, GS | 1 |
| Ibragimova, GV | 1 |
| Beĭsugurov, MSh | 1 |
| Shmushkovich, BI | 1 |
| Pan, CH | 1 |
| Chiang, CY | 1 |
| Chen, SS | 1 |
| Ishigaki, Y | 1 |
| Komiya, T | 3 |
| Tsuda, H | 1 |
| Nyberg-Hansen, R | 1 |
| Gjerstad, L | 1 |
| Sakano, T | 1 |
| Hamasaki, T | 1 |
| Shimizu, H | 1 |
| Harada, Y | 1 |
| Ueda, K | 1 |
| Lobzin, VS | 2 |
| Poliakova, LA | 1 |
| Fedotova, TA | 1 |
| Obata, S | 1 |
| Knox, AJ | 1 |
| Bowker, AM | 1 |
| Sumner, DW | 1 |
| Muers, MF | 1 |
| Tojo, M | 1 |
| Sakuragawa, N | 1 |
| Nonaka, I | 1 |
| Obolenskiĭ, SV | 1 |
| Rolle, MN | 1 |
| Zhulev, NM | 1 |
| Smirnov, AN | 1 |
| Gladyshev, SS | 1 |
| Satoh, A | 1 |
| Takashima, H | 1 |
| Hazama, R | 1 |
| Kan, H | 1 |
| Fujimoto, S | 1 |
| Matsuda, I | 1 |
| Kanazawa, K | 1 |
| Takeuchi, S | 1 |
| Bammer, HG | 1 |
| Cape, CA | 1 |
| Patten, BM | 1 |
| Oliver, KL | 1 |
| Engel, WK | 1 |
| Skeggs, DB | 1 |
| Yanagizawa, N | 1 |
| Tsukagoshi, H | 1 |
| Mackay, IR | 1 |
| Smalley, M | 1 |
| Durance, RA | 1 |
| Hamilton, EB | 1 |
| Huber, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study[NCT00987116] | Phase 4 | 118 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients[NCT00309088] | Phase 3 | 80 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients[NCT04096222] | 42 participants (Anticipated) | Observational | 2021-06-29 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for prednisolone and Myasthenia Gravis
| Article | Year |
|---|---|
Minimal symptom expression achievement over time in generalized myasthenia gravis.
Topics: Activities of Daily Living; Autoantibodies; Humans; Myasthenia Gravis; Prednisolone; Receptors, Chol | 2023 |
Very late onset of myasthenia gravis: case report and brief review of the literature.
Topics: Age of Onset; Aged, 80 and over; Cholinesterase Inhibitors; Female; Glucocorticoids; Humans; Myasthe | 2020 |
Concurrent thyrolipomatosis and thymolipoma in a patient with myasthenia gravis: a case report and review of the literature.
Topics: Adult; Humans; Lipoma; Lipomatosis; Male; Myasthenia Gravis; Prednisolone; Pyridostigmine Bromide; T | 2021 |
Rationale for the clinical guidelines for myasthenia gravis in Japan.
Topics: Antibodies; Calcineurin Inhibitors; Cholinergic Antagonists; Humans; Immunosuppressive Agents; Japan | 2018 |
[Therapeutic strategies against myasthenia gravis].
Topics: Adrenal Cortex Hormones; Calcineurin Inhibitors; Humans; Immunosuppressive Agents; Myasthenia Gravis | 2013 |
[Clinical factors affecting quality of life and treatment targets in patients with myasthenia gravis].
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Cushing Syndrome; Depression; Female; Follow-U | 2013 |
[Treatment of pure ocular myasthenia: a proposal from Japan MG registry 2012].
Topics: Blepharoptosis; Calcineurin Inhibitors; Cholinesterase Inhibitors; Diplopia; Disease Progression; Hu | 2013 |
Rituximab for myasthenia gravis: three case reports and review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-L | 2009 |
[Current status and future prospects of therapy for myasthenia gravis: considering thymectomy].
Topics: Humans; Myasthenia Gravis; Prednisolone; Thymectomy | 2011 |
[Myasthenia gravis].
Topics: Autoantibodies; Combined Modality Therapy; Diagnosis, Differential; Humans; Immunoglobulins, Intrave | 2004 |
Immunosuppressive agents for myasthenia gravis.
Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Hu | 2007 |
When the patient fails to respond to treatment: myasthenia gravis.
Topics: Autoantibodies; Diagnosis, Differential; Diagnostic Errors; Humans; Medication Errors; Myasthenia Gr | 2007 |
[Myasthenia gravis].
Topics: Child; Cholinesterase Inhibitors; Curare; Edrophonium; Electromyography; Humans; Infant, Newborn; Mu | 1982 |
Therapy of myasthenic crisis.
Topics: Humans; Myasthenia Gravis; Plasma Exchange; Prednisolone; Pyridostigmine Bromide; Respiratory Insuff | 1997 |
[A case of nephrotic syndrome associated with myasthenia gravis and malignant thymoma].
Topics: Adult; Anti-Inflammatory Agents; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Kidney; | 1999 |
[Subacute motor neuronopathy associated with myasthenia gravis and thymoma].
Topics: Autoantibodies; Autoimmunity; Female; Humans; Middle Aged; Motor Neuron Disease; Myasthenia Gravis; | 1999 |
[A case of myasthenia gravis, who developed minimal change nephrotic syndrome during immunosuppressive therapy after thymectomy].
Topics: Azathioprine; Female; Humans; Immunosuppressive Agents; Middle Aged; Myasthenia Gravis; Nephrosis, L | 2000 |
Myasthenia gravis associated with reduced masticatory function.
Topics: Adult; Bite Force; Combined Modality Therapy; Female; Glucocorticoids; Humans; Mastication; Masticat | 2000 |
Bulbar presentations of myasthenia gravis in the elderly patient.
Topics: Aged; Blepharoptosis; Cholinesterase Inhibitors; Deglutition Disorders; Diplopia; Dysarthria; Glucoc | 2001 |
[Juvenile myasthenia gravis].
Topics: Adolescent; Adult; Autoantibodies; Child; Child, Preschool; Cholinesterase Inhibitors; Diagnosis, Di | 2000 |
[Myasthenia gravis associated with HIV infection].
Topics: Autoantibodies; Biomarkers; Cholinesterase Inhibitors; Drug Therapy, Combination; Globins; HIV Infec | 2001 |
[Steroid therapy for neurologic diseases--indications and methods of administration].
Topics: Adrenocorticotropic Hormone; Cortisone; Facial Paralysis; Female; Humans; Middle Aged; Multiple Scle | 1979 |
[Myasthenia gravis and antiacetylcholine receptor antibody (author's transl)].
Topics: Adult; Animals; Autoantibodies; Cattle; Female; Humans; Infant, Newborn; Male; Maternal-Fetal Exchan | 1979 |
[Diagnosis and surgical treatment of myasthenia gravis in childhood].
Topics: Adolescent; Child; Cholinesterase Inhibitors; Dexamethasone; Humans; Lymph Node Excision; Myasthenia | 1991 |
[Clinical analysis of myasthenia gravis accompanied by invasive thymoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Huma | 1991 |
[Immunosuppressive therapy of various autoimmune diseases of the nervous system].
Topics: Autoimmune Diseases; Azathioprine; Cyclophosphamide; Drug Evaluation; Humans; Multiple Sclerosis; My | 1990 |
Thymolipoma in patients with myasthenia gravis: report of two cases and review.
Topics: Azathioprine; Female; Humans; Lipoma; Middle Aged; Myasthenia Gravis; Prednisolone; Thymus Neoplasms | 1988 |
13 trials available for prednisolone and Myasthenia Gravis
| Article | Year |
|---|---|
Cladribine in myasthenia gravis: a pilot open-label study.
Topics: Adult; Aged; Aged, 80 and over; Cladribine; Drug Resistance; Drug Therapy, Combination; Female; Huma | 2020 |
Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Drug Administration Schedule; Female; Glucocorti | 2021 |
Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Topics: Activities of Daily Living; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imm | 2011 |
Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; | 2011 |
Long-term treatment of myasthenia gravis with immunoadsorption.
Topics: Adult; Aged; Autoantibodies; Azathioprine; Female; Humans; Immunosorbent Techniques; Immunosuppressi | 2002 |
Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azathioprine; Daunorubic | 2004 |
Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studi | 2005 |
Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Antibodies; Drug Therapy, Combination; | 2006 |
Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Topics: Adult; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Middl | 2006 |
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies; Cytokines; Dose-Re | 2008 |
Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; H | 2008 |
[Long-term effects of plasma exchange in myasthenia. Results of a randomized study].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Male; Middle Aged; Myasthen | 1983 |
A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies; Azathioprine; Double-Blind Method; Drug Ther | 1998 |
212 other studies available for prednisolone and Myasthenia Gravis
| Article | Year |
|---|---|
Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy.
Topics: Adrenal Cortex Hormones; Humans; Myasthenia Gravis; Prednisolone; Prognosis; Retrospective Studies; | 2022 |
A case of autoimmune hepatitis with thymoma and myasthenia gravis.
Topics: Adult; Female; Hepatitis, Autoimmune; Humans; Myasthenia Gravis; Neoplasm Recurrence, Local; Prednis | 2022 |
Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Topics: Humans; Interleukin-2; Myasthenia Gravis; Prednisolone; Prednisone; Quality of Life; Tacrolimus; Tra | 2022 |
Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018.
Topics: Activities of Daily Living; Adult; Aged; Autoantibodies; Edrophonium; Esterases; Female; Humans; Imm | 2022 |
Tailoring Two Chemometric Models for Determination of Three Neuromuscular Combined Medications and Application to Spiked Human Plasma.
Topics: Chemometrics; Humans; Mercaptopurine; Myasthenia Gravis; Prednisolone; Pyridostigmine Bromide; Unite | 2023 |
[The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
Topics: Activities of Daily Living; Humans; Myasthenia Gravis; Patients; Prednisolone; Prospective Studies | 2022 |
[The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
Topics: Activities of Daily Living; Humans; Myasthenia Gravis; Patients; Prednisolone; Prospective Studies | 2022 |
[The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
Topics: Activities of Daily Living; Humans; Myasthenia Gravis; Patients; Prednisolone; Prospective Studies | 2022 |
[The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
Topics: Activities of Daily Living; Humans; Myasthenia Gravis; Patients; Prednisolone; Prospective Studies | 2022 |
"Mummy, my eyelids are heavy": A case series of juvenile myasthenia gravis.
Topics: Autoantibodies; Blepharoptosis; Child, Preschool; Cholinesterase Inhibitors; Diseases in Twins; Drug | 2021 |
Thymoma complicated with myasthenia gravis and Good syndrome - a therapeutic conundrum: a case report.
Topics: Adult; Combined Modality Therapy; Humans; Immunoglobulins, Intravenous; Immunologic Deficiency Syndr | 2019 |
Importance of clinical tests in ocular myasthenia.
Topics: Blepharoptosis; Cholinesterase Inhibitors; Cold Temperature; Diagnosis, Differential; Diagnostic Tec | 2019 |
[A case of myasthenia gravis developed during pembrolizumab administration, suggesting an excitation-contraction connection disorder].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Female; Humans; Middle Aged; Myasthenia Gra | 2020 |
"Initial deterioration" upon intravenous methyl-prednisolon in myasthenia is multifactorial.
Topics: Administration, Intravenous; Humans; Immunosuppressive Agents; Methylprednisolone; Muscle Weakness; | 2020 |
Myasthenic crisis and late deep vein thrombosis following thymectomy in a patient with myasthenia gravis: A case report.
Topics: Aged; Anticoagulants; Cholinesterase Inhibitors; Heparin, Low-Molecular-Weight; Humans; Hyperlactate | 2020 |
Ptosis that resolves with application of an ice pack.
Topics: Anti-Inflammatory Agents; Blepharoptosis; Cholinesterase Inhibitors; Cryotherapy; Humans; Ice; Male; | 2020 |
Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report.
Topics: Aged, 80 and over; Antibodies; Coronary Vasospasm; Electrocardiography; Female; Humans; Immunoglobul | 2020 |
[A case of anti-MuSK positive MG with recurrent right-sided heart failure as the initial manifestation].
Topics: Autoantibodies; Biomarkers; Female; Heart Failure; Humans; Immunoglobulins, Intravenous; Immunosuppr | 2020 |
[Eclizumab in the treatment of myasthenia gravis crisis complicating invasive thymoma: a case study of efficacy].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autoantibo | 2020 |
Comparison of quality of life and activity of daily living status of patients with myasthenia gravis treated with low-dose and high-dose prednisolone.
Topics: Activities of Daily Living; Humans; Myasthenia Gravis; Prednisolone; Quality of Life; Surveys and Qu | 2020 |
Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection.
Topics: Adult; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Myasthenia | 2020 |
Myasthenia gravis masquerading as acute stroke: a case report.
Topics: Diagnosis, Differential; Diagnostic Errors; Drug Therapy, Combination; Humans; Ischemic Stroke; Male | 2020 |
Trauma-induced myasthenia gravis: coincidence or causal relationship?
Topics: Blepharoptosis; Diplopia; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisolone; Pyridostigmine | 2021 |
Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Autoantigens; Cholinesterase Inhibitors; COVID-19; | 2021 |
Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
Topics: Aged; Antibodies, Monoclonal; Autoantibodies; Blepharoptosis; Carcinoma, Non-Small-Cell Lung; Creati | 2017 |
Unilateral-external Ophthalmoplegia: ARare Presentation of Myasthenia Gravis.
Topics: Adult; Cholinesterase Inhibitors; Humans; Male; Myasthenia Gravis; Ophthalmoplegia; Prednisolone; Py | 2016 |
A case of myasthenia gravis and myositis induced by nivolumab.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Immunoglo | 2017 |
A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Topics: Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myasthenia G | 2017 |
Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Dose-Resp | 2018 |
Outcome of Myasthenia gravis treated with high-dose prednisolone and azathioprine: A single centre ambispective study from India.
Topics: Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myasthenia | 2017 |
Rheumatoid meningitis developed in patient with stable rheumatoid arthritis and myasthenia gravis-detailed analysis of intracranial inflammation using flow cytometry.
Topics: Adult; Anti-Inflammatory Agents; Antigens, CD; Arthritis, Rheumatoid; Female; Flow Cytometry; Humans | 2018 |
Myasthenia gravis unmasked by imatinib.
Topics: Adult; Blepharoptosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 2019 |
Ocular myasthenia gravis patients following the administration of tacrolimus and steroids.
Topics: Blepharoptosis; Child, Preschool; Female; Humans; Immunosuppressive Agents; Male; Myasthenia Gravis; | 2019 |
Hypophonia as only presenting symptom in myasthenia gravis - a diagnostic dilemma in poor countries: a case report.
Topics: Anti-Inflammatory Agents; Bulbar Palsy, Progressive; Cholinesterase Inhibitors; Dysphonia; Female; H | 2019 |
Myasthenic crisis following iodinated contrast material (iohexol) aspiration: a case report.
Topics: Cholinesterase Inhibitors; Contrast Media; Deglutition Disorders; Disease Progression; Glucocorticoi | 2019 |
Respiratory failure in clustered acetylcholine receptor autoantibody-positive myasthenia gravis.
Topics: Aged; Autoantibodies; Humans; Immunoglobulins; Male; Myasthenia Gravis; Prednisolone; Receptors, Cho | 2019 |
[A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Topics: Autoantibodies; Biomarkers; Carcinoma, Squamous Cell; Connectin; Humans; Lung Neoplasms; Male; Middl | 2019 |
[A case of myasthenia gravis and myositis induced by pembrolizumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Autoa | 2019 |
Putative paraneoplastic pemphigus and myasthenia gravis in a cat with a lymphocytic thymoma.
Topics: Animals; Cat Diseases; Cats; Female; Lymphoma; Myasthenia Gravis; Pemphigus; Prednisolone; Pyridosti | 2013 |
[Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis].
Topics: Administration, Oral; Cross-Sectional Studies; Humans; Myasthenia Gravis; Prednisolone; Quality of L | 2013 |
[Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
Topics: Calcineurin Inhibitors; Cyclosporine; Immunoglobulins, Intravenous; Japan; Myasthenia Gravis; Predni | 2013 |
Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mya | 2013 |
Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis.
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Edema; Humans; Male; Myasthenia Gravis; Predni | 2014 |
"Why do I always see double?" A misdiagnosed case of ocular myasthenia gravis for 10 years.
Topics: Anti-Inflammatory Agents; Blepharoptosis; Cholinesterase Inhibitors; Diagnosis, Differential; Diagno | 2014 |
Fatal Strongyloides hyper-infection in a patient with myasthenia gravis.
Topics: Albendazole; Antinematodal Agents; Endemic Diseases; Fatal Outcome; Humans; Immunocompromised Host; | 2014 |
Quality of life in purely ocular myasthenia in Japan.
Topics: Anti-Inflammatory Agents; Cholinesterase Inhibitors; Cross-Sectional Studies; Female; Humans; Japan; | 2014 |
Appearance of thymoma 5 years after thymectomy for nonthymomatous myasthenia gravis.
Topics: Anti-Inflammatory Agents; Antibodies; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male | 2014 |
Oral corticosteroid therapy and present disease status in myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Combined | 2015 |
Acute unilateral isolated ptosis.
Topics: Blepharoptosis; Diagnosis, Differential; Diplopia; Eye Movements; Eyelids; Horner Syndrome; Humans; | 2015 |
Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis.
Topics: Age of Onset; Aged; Autoantibodies; Cholinesterase Inhibitors; Female; Glucocorticoids; Humans; Long | 2015 |
New diagnosis myasthenia gravis and preeclampsia in late pregnancy.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Local; Antihypertensive Agents; Cesarean Section; Cholineste | 2015 |
Lung cancer associated with seronegative myasthenia gravis.
Topics: Blepharoptosis; Diplopia; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Myasthenia Gravi | 2015 |
Anti-MuSK Antibody-positive Myasthenia Gravis Mimicking Amyotrophic Lateral Sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Autoantibodies; Biomarkers; Deglutition Disorders; Disease Prog | 2015 |
Reversible tongue muscle atrophy accelerated by early initiation of immunotherapy in anti-MuSK myasthenia gravis: A case report.
Topics: Aged; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Muscular Atrophy; Myastheni | 2016 |
Multidisciplinary treatment for prepubertal juvenile myasthenia gravis with crisis.
Topics: Biopsy; Child; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Imm | 2016 |
Early fast-acting treatment strategy against generalized myasthenia gravis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cohort Studies; Female; Humans; Immunotherapy; Japan; Male; M | 2017 |
Myasthenia Gravis and Its Aeromedical Implications.
Topics: Adult; Aerospace Medicine; Aged; Aviation; Azathioprine; Certification; Cholinesterase Inhibitors; D | 2017 |
Adequate tacrolimus concentration for myasthenia gravis treatment.
Topics: Adult; Aged; Autoantibodies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hu | 2017 |
Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Depression; Female; Humans; Income; Japan; | 2017 |
Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
Topics: Drug Therapy, Combination; Humans; Immunotherapy; Myasthenia Gravis; Mycophenolic Acid; Prednisolone | 2008 |
Case of generalised myasthenia gravis with membranous nephropathy.
Topics: Adult; Blepharoptosis; Female; Glomerulonephritis, Membranous; Humans; Kidney Failure, Chronic; Myas | 2008 |
P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: clinical implications and influence of glucocorticoid administration.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4-Positive T-Lymphocytes; CD | 2009 |
Decompensating esophoria as the presenting feature of myasthenia gravis.
Topics: Adult; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Esotropia; Female; Humans; Myasthenia Gr | 2009 |
Long-term effects of combined immunosuppressive treatment on myasthenic crisis.
Topics: Adult; Aged; Azathioprine; Case-Control Studies; Chi-Square Distribution; Clinical Trials as Topic; | 2009 |
Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients.
Topics: Adult; Aged; Aged, 80 and over; Autoimmunity; Case-Control Studies; Cell Proliferation; Coculture Te | 2009 |
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressi
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, R | 2010 |
Efficacy of tacrolimus against Churg-Strauss syndrome in a patient with myasthenia gravis.
Topics: Aged; Asthma; Blood Vessels; Churg-Strauss Syndrome; Comorbidity; Eosinophilia; Female; Humans; Immu | 2010 |
Muscle-specific tyrosine kinase-antibody-positive myasthenic crisis with detailed electrophysiologic studies.
Topics: Aged; Anti-Inflammatory Agents; Electromyography; Humans; Male; Myasthenia Gravis; Plasmapheresis; P | 2009 |
Myasthenia gravis and autoimmune Addison disease in a patient with thymoma.
Topics: Acetylcholine; Addison Disease; Administration, Oral; Adult; Anti-Inflammatory Agents; Antineoplasti | 2009 |
Autoimmune polyglandular syndrome type 2 with myasthenia gravis crisis.
Topics: Aged; Female; Glucocorticoids; Humans; Myasthenia Gravis; Plasmapheresis; Polyendocrinopathies, Auto | 2009 |
Pseudo-internuclear ophthalmoplegia as a sign of overlapping myasthenia gravis in a patient with 'intractable' hypothyroidism.
Topics: Anti-Inflammatory Agents; Cholinesterase Inhibitors; Edrophonium; Humans; Hypothyroidism; Male; Midd | 2010 |
Long-term follow up of thymus in patients with myasthenia gravis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Female; Humans; Immunosuppressive Agents; | 2010 |
Combined treatment with prednisolone and tacrolimus for myasthenia gravis with invasive thymoma.
Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Male; | 2010 |
Early aggressive treatment strategy against myasthenia gravis.
Topics: Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Methylprednisolone; Myasthenia G | 2011 |
[Anti-acetylcholine receptor antibodies: effect of immunosuppressive drug therapy in patients with myasthenia gravis].
Topics: Adolescent; Adult; Aged; Autoantibodies; Biomarkers; Child; Female; Glucocorticoids; Humans; Immunos | 2010 |
Candida esophagitis as the cause of swallowing disturbances in an 85-year-old patient with myasthenia gravis.
Topics: Aged; Antifungal Agents; Candidiasis; Deglutition Disorders; Diagnosis, Differential; Drug Therapy, | 2011 |
Myasthenia gravis can cause camptocormia.
Topics: Aged; Cholinesterase Inhibitors; Edrophonium; Electromyography; Female; Humans; Muscular Atrophy, Sp | 2012 |
Resolution of autoimmune oophoritis after thymectomy in a myasthenia gravis patient.
Topics: Amenorrhea; Bipolar Disorder; Female; Humans; Myasthenia Gravis; Oophoritis; Ovarian Cysts; Ovarian | 2011 |
[Predictive analysis for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis].
Topics: Adult; Aged; Anesthesia, General; Female; Forecasting; Humans; Logistic Models; Male; Middle Aged; M | 2012 |
A 90 year old man with difficulty swallowing and proximal muscle weakness.
Topics: Aged, 80 and over; Cholinesterase Inhibitors; Deglutition Disorders; Diagnosis, Differential; Fatal | 2012 |
Ice pack test: is it obsolete?
Topics: Adult; Blepharoptosis; Cholinesterase Inhibitors; Diagnosis, Differential; Diplopia; Glucocorticoids | 2011 |
Thymoma hyalinized by steroid therapy in myasthenia gravis.
Topics: Aged; Female; Glucocorticoids; Humans; Hyalin; Myasthenia Gravis; Prednisolone; Thymoma; Thymus Neop | 2012 |
[Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids].
Topics: Calcineurin Inhibitors; Cyclosporine; Emulsions; Humans; Myasthenia Gravis; Prednisolone; Quality of | 2012 |
Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis.
Topics: Aged, 80 and over; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female | 2013 |
The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents; Autoantibodies; Blepharoptosis; Cholinesterase | 2013 |
Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunoglobulins, Intravenous; Intensive Care Units; | 2014 |
[Demographic and clinical characteristics of patients with myasthenia gravis].
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents; Blepharoptosis; Cholinesterase Inhibitors; Diplo | 2002 |
Low-dose tacrolimus for intractable myasthenia gravis.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Drug Therapy, Combination; Female; Humans; Immunosu | 2002 |
Antiphospholipid syndrome and multiple ischemic strokes in a patient with myasthenia gravis.
Topics: Antiphospholipid Syndrome; Female; Glucocorticoids; Humans; Middle Aged; Myasthenia Gravis; Predniso | 2002 |
Relapse of ocular symptoms after remission of myasthenia gravis--a comparison of relapsed and complete remission cases.
Topics: Adolescent; Adult; Eye Diseases; Female; Glucocorticoids; Humans; Infant, Newborn; Male; Middle Aged | 2003 |
[Pneumatosis intestinalis in a patient of myasthenia gravis treated with high-dose corticosteroid].
Topics: Adult; Anti-Inflammatory Agents; Diarrhea; Female; Humans; Myasthenia Gravis; Pneumatosis Cystoides | 2003 |
Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Topics: Adult; Aged; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; | 2003 |
Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Autoantibodies; Bone Density; Cross-Sectiona | 2004 |
Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis.
Topics: Adult; Combined Modality Therapy; Female; Glucocorticoids; Humans; Male; Mediastinum; Multivariate A | 2004 |
Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Immunosuppressive Agents; Myasthenia Gravis; Osteopo | 2004 |
[A constrictive pericarditis on oral steroid and immunosuppressant treated with bilateral anterolateral thoracotomy; report of a case].
Topics: Anti-Inflammatory Agents; Cyclosporine; Humans; Immunosuppressive Agents; Male; Methenolone; Middle | 2004 |
Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy.
Topics: Adult; Antibodies; Antineoplastic Agents, Hormonal; Drug Interactions; Humans; Immunoglobulins, Intr | 2005 |
[Prognosis of patients with myasthenia gravis].
Topics: Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Ocular Motility Diso | 2005 |
An elderly man with dysphagia and dysarthria.
Topics: Aged, 80 and over; Cholinesterase Inhibitors; Deglutition Disorders; Diagnosis, Differential; Dysart | 2005 |
Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies; Antibodies, Monoclonal; Antibodies, M | 2006 |
[Ocular involvement in MuSK antibody-positive myasthenia gravis].
Topics: Adult; Autoantibodies; Autoimmune Diseases; Azathioprine; Drug Therapy, Combination; Female; Humans; | 2006 |
Anti-MuSK antibodies in a case of ocular myasthenia gravis.
Topics: Adult; Antibodies; Humans; Male; Myasthenia Gravis; Prednisolone; Receptor Protein-Tyrosine Kinases; | 2006 |
Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
Topics: Adult; Aged; Cholinesterase Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Humans; | 2007 |
A case of systemic lupus erythematosus complicated by pure red cell aplasia and idiopathic portal hypertension after thymectomy.
Topics: Adult; Female; Humans; Hypertension, Portal; Lupus Erythematosus, Systemic; Myasthenia Gravis; Posto | 2006 |
Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
Topics: Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2006 |
Longstanding right-hand weakness in a patient with myasthenia gravis.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Chronic Disease; Disease Progression; Electric Stim | 2006 |
[A case of myasthenia gravis appearing after thymomectomy: with histopathological investigation].
Topics: Anti-Inflammatory Agents; Humans; Male; Middle Aged; Myasthenia Gravis; Postoperative Complications; | 2006 |
Myasthenia gravis disclosed by lithium carbonate.
Topics: Adult; Anti-Inflammatory Agents; Antimanic Agents; Bipolar Disorder; Cholinesterase Inhibitors; Fati | 2006 |
Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia.
Topics: Clone Cells; Cyclosporine; Female; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; Gene Rear | 2006 |
Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
Topics: Adult; Cyclosporine; Diabetic Nephropathies; Drug Evaluation; Female; Humans; Hypertension, Renal; I | 2007 |
Vocal cord paralysis in myasthenia gravis with anti-MuSK antibodies.
Topics: Autoantibodies; Biomarkers; Bulbar Palsy, Progressive; Deglutition Disorders; Facial Muscles; Humans | 2007 |
Concurrence of non-myasthenic symptoms with myasthenia gravis.
Topics: Adult; Aged; Ambenonium Chloride; Blepharoptosis; Dysgeusia; Dyskinesia, Drug-Induced; Female; Human | 2007 |
Myasthenia gravis and diabetes mellitus: a 35-year retrospective study.
Topics: Aged; Aged, 80 and over; Autoantibodies; Diabetes Mellitus; Dose-Response Relationship, Drug; Female | 2007 |
Case of severe refractory myasthenia gravis in HUKM.
Topics: Adult; Cyclosporine; Female; Humans; Immunoglobulins; Immunosuppressive Agents; Myasthenia Gravis; M | 2006 |
[Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report].
Topics: Autoantibodies; Biomarkers; Drug Administration Schedule; Female; Glucocorticoids; Humans; Middle Ag | 2007 |
[Concurrence of myasthenia gravis, polymyositis, thyroiditis and eosinophilia in a patient with type B1 thymoma].
Topics: Adrenal Cortex Hormones; Adult; Eosinophilia; Female; Humans; Methylprednisolone; Myasthenia Gravis; | 2007 |
A cause of reversible dysphagia: an unusual presentation of myasthenia gravis.
Topics: Aged, 80 and over; Cholinesterase Inhibitors; Deglutition Disorders; Diagnosis, Differential; Female | 2008 |
[Indication of thymectomy and immunotherapies on myasthenia gravis].
Topics: Aged; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Myasthenia Gravis; Prednisolo | 2007 |
Preoperative steroid therapy stabilizes postoperative respiratory condition in myasthenia gravis.
Topics: Ambenonium Chloride; Cholinesterase Inhibitors; Combined Modality Therapy; Glucocorticoids; Humans; | 2008 |
Preoperative steroid therapy stabilizes postoperative respiratory conditions in myasthenia gravis.
Topics: Adult; Aged; Ambenonium Chloride; Cholinesterase Inhibitors; Combined Modality Therapy; Female; Huma | 2008 |
Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; El | 1984 |
Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone/azathioprine in myasthenia gravis.
Topics: Adult; Aged; Autoantibodies; Azathioprine; Brachial Plexus; Electric Stimulation; Female; Humans; Ma | 1982 |
[Characteristics of anesthesiological assistance for parturients with myasthenia gravis].
Topics: Adult; Anesthesia, Endotracheal; Anesthesia, Obstetrical; Cholinesterase Inhibitors; Electric Stimul | 1984 |
[A case of myasthenia gravis complicated by cortisol-producing adrenal adenoma].
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Cushing Syndrome; Female; Humans; Hydrocortisone; Myastheni | 1984 |
Specific involvement of peripheral T lymphocytes against acetylcholine receptors in myasthenia gravis.
Topics: Adolescent; Adult; Autoantigens; Child; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Predni | 1983 |
[Thymectomy for the treatment of thymoma--concomitant administration of large doses of prednisolone on alternate days before and after the surgical procedure].
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle A | 1983 |
[Corticosteroid therapy combined with thymectomy in myasthenia gravis].
Topics: Adult; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisolone | 1983 |
[Pre- and postoperative care of thymectomy in patients with myasthenia gravis].
Topics: Adolescent; Adult; Female; Humans; Infant; Myasthenia Gravis; Neostigmine; Postoperative Care; Predn | 1982 |
Plasma pyridostigmine levels in myasthenia gravis.
Topics: Biological Availability; Humans; Myasthenia Gravis; Prednisolone; Pyridostigmine Bromide | 1981 |
[Clinical importance of the electron microscopic study of muscle biopsies in myasthenia during prednisolone therapy].
Topics: Adult; Biopsy; Chronic Disease; Drug Evaluation; Female; Humans; Microscopy, Electron; Muscles; Myas | 1981 |
Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy.
Topics: Acetylcholine; Adult; Aged; Antibodies; Azathioprine; Female; Humans; Immunosuppression Therapy; Mal | 1980 |
Steroid treatment for experimental autoimmune myasthenia gravis.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Female; Membrane Potentials; Motor Endplate; M | 1980 |
[A patient with a relapse of myasthenia gravis after a 13-year remission following successful treatment by mediastinal irradiation and corticosteroid therapy].
Topics: Adult; Humans; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Male; My | 1995 |
A case of myasthenia gravis accompanied by invasive thymoma, alopecia areata and dry mouth.
Topics: Adult; Alopecia Areata; Edrophonium; Humans; Immune System Diseases; Magnetic Resonance Imaging; Mal | 1995 |
Myasthenia gravis associated with Addison's disease.
Topics: Addison Disease; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisolone | 1994 |
Myasthenia gravis after allogeneic bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Graft vs Host Disease; HLA-B7 Ant | 1994 |
Acute neuromuscular respiratory paralysis.
Topics: Acute Disease; Aged; Female; Humans; Myasthenia Gravis; Peak Expiratory Flow Rate; Prednisolone; Res | 1994 |
Breathing pattern and central ventilatory drive in mild and moderate generalised myasthenia gravis.
Topics: Adult; Aged; Cholinesterase Inhibitors; Female; Humans; Lung; Male; Middle Aged; Myasthenia Gravis; | 1994 |
Treatment of myasthenia gravis: a comparison of the natural course and current therapies.
Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Combined Modality Therapy; Evaluation Studies as | 1993 |
Coexistence of Parkinson's disease and myasthenia gravis: a case report.
Topics: Brain; Cholinesterase Inhibitors; Female; Humans; Middle Aged; Myasthenia Gravis; Parkinson Disease; | 1993 |
Lymphocytapheresis in combination with immunosuppressive drugs for refractory myasthenia gravis: two-color flow cytometric analysis of changes in peripheral blood lymphocyte subsets.
Topics: Autoantibodies; Azathioprine; Combined Modality Therapy; Drug Therapy, Combination; Female; Flow Cyt | 1995 |
Seronegative myasthenia gravis associated with atonic urinary bladder and accommodative insufficiency.
Topics: Accommodation, Ocular; Adult; Drug Therapy, Combination; Edrophonium; Female; Humans; Muscle Tonus; | 1995 |
Hypereosinophilic syndrome with generalized myasthenia gravis.
Topics: Blood Proteins; Child; Eosinophil Granule Proteins; Eosinophils; Female; Glucocorticoids; Humans; Hy | 1996 |
Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment.
Topics: Adolescent; Adult; Aged; Azathioprine; Brain; Female; Humans; Immunosuppression Therapy; Male; Memor | 1996 |
[Polymyositis followed by myasthenia gravis].
Topics: Anti-Inflammatory Agents; Female; Humans; Middle Aged; Myasthenia Gravis; Polymyositis; Prednisolone | 1996 |
Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Child; Drug Administr | 1997 |
Myasthenia gravis and alopecia areata.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Child, Preschool; Female; Humans; Infant; Male; Mid | 1997 |
[Myasthenic crisis caused by azathioprine-induced fever].
Topics: Aged; Azathioprine; Critical Care; Drug Hypersensitivity; Drug Therapy, Combination; Fever; Humans; | 1997 |
Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients.
Topics: Adolescent; Antibodies; Azathioprine; Child; Drug Combinations; Female; Follow-Up Studies; Glucocort | 1997 |
Alopecia areata associated with myasthenia gravis and thymoma: a case of alopecia with marked improvement following thymectomy and high level prednisolone administration.
Topics: Alopecia Areata; Combined Modality Therapy; Female; Follow-Up Studies; Glucocorticoids; Humans; Midd | 1997 |
Multiple liver hemangiomas enlargement during long-term steroid therapy for myasthenia gravis.
Topics: Embolization, Therapeutic; Female; Glucocorticoids; Hemangioma, Cavernous; Hepatectomy; Humans; Live | 1998 |
Adjuvant therapy in invasive thymoma: an audit of cases treated over an 8 year period.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; An | 1999 |
[A rare case of severe generalized myasthenia against a background of pregnancy].
Topics: Adult; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Female; Humans; Infant, Newborn; Male; M | 2000 |
Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
Topics: Adult; Anti-Inflammatory Agents; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosupp | 2000 |
[A case of myasthenia gravis following sarcoidosis and Hashimoto's thyroiditis].
Topics: Aged; Autoantibodies; Biomarkers; Female; Humans; Immunity, Cellular; Myasthenia Gravis; Prednisolon | 2000 |
Myasthenia gravis, corticosteroids and osteoporosis prophylaxis.
Topics: Adrenal Cortex Hormones; Guideline Adherence; Humans; Myasthenia Gravis; Osteoporosis; Prednisolone; | 2001 |
A case of myasthenia gravis accompanied by erythema elevatum diutinum and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Erythema; Female; Humans; Middle Aged; Myasthenia G | 2001 |
A case with myasthenia gravis (MG) emerging after splenectomy for idiopathic thrombocytopenic purpura (ITP): possible effects of thymectomy on autoantibodies.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Cholinesterase Inhibitors; Combined Modality Therap | 2000 |
Thyroid gland tumour, pemphigus foliaceus and myasthenia gravis in the daughter of a woman with myasthenia gravis.
Topics: Adult; Ambenonium Chloride; Antibodies; Carcinoma, Papillary; Cholinesterase Inhibitors; Complement | 2001 |
Presentation of myasthenia gravis mimicking blepharospasm.
Topics: Aged; Azathioprine; Blepharospasm; Cholinesterase Inhibitors; Diagnostic Errors; Electromyography; G | 2002 |
Steroid therapy without primary dose escalation for postthymectomy crisis in 2 thymomatous myasthenia gravis patients.
Topics: Adult; Autoantibodies; Female; Humans; Middle Aged; Myasthenia Gravis; Postoperative Complications; | 2002 |
Acute severe ocular myasthenia in a 92-year-old woman.
Topics: Acute Disease; Age of Onset; Aged; Aged, 80 and over; Female; Glucocorticoids; Humans; Myasthenia Gr | 2002 |
Long-term follow-up of myasthenia gravis patients with hyperthyroidism.
Topics: Adult; Anti-Inflammatory Agents; Antithyroid Agents; Autoantibodies; Female; Follow-Up Studies; Huma | 2002 |
Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis.
Topics: Adult; Aged; Azathioprine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myasthenia Gravis; | 1979 |
Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis.
Topics: Adrenal Cortex Hormones; Animals; Dexamethasone; Diaphragm; Female; Hemicholinium 3; Hydrocortisone; | 1976 |
Effect of corticosteroids on sciatic nerve-tibialis anterior muscle of rats treated with hemicholinium-3. An experimental approach to a possible mechanism of action of corticosteroids in myasthenia gravis.
Topics: Animals; Betamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glucocorti | 1977 |
Short-term effects of prednisolone on neuromuscular transmission in normal rats and those with experimental autoimmune myasthenia gravis.
Topics: Action Potentials; Animals; Autoimmune Diseases; Dose-Response Relationship, Drug; Female; Membrane | 1979 |
Effects of myasthenic immunoglobulins and of prednisolone on spontaneous miniature end-plate potentials in mouse diaphragms.
Topics: Animals; Diaphragm; Immunoglobulins; Membrane Potentials; Mice; Motor Endplate; Myasthenia Gravis; N | 1979 |
[Adrenal cortex steroid-responsive myasthenic neuromyopathy].
Topics: Adult; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Diseases; Prednisolone | 1977 |
[Efficacy and limitation of steroid therapy--comparison of polymyositis and myasthenia gravis].
Topics: Adult; Female; Humans; Male; Myasthenia Gravis; Myositis; Prednisolone | 1978 |
[Myasthenia gravis. Longitudinal course and therapeutic aspects].
Topics: Adult; Azathioprine; Cholinesterase Inhibitors; Cosyntropin; Drug Therapy, Combination; Enzyme Inhib | 1978 |
Experimental autoimmune myasthenia gravis in rats. Modification by thymectomy and prednisolone.
Topics: Action Potentials; Animals; Autoimmune Diseases; Myasthenia Gravis; Prednisolone; Rats; Thymectomy; | 1977 |
A case of myasthenia gravis treated with steroids: some suggestions for the mechanisms underlying their effect.
Topics: Cholinesterase Inhibitors; Edrophonium; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisolone | 1977 |
[Cell electrophoretic studies of lymphocytes. 3. Effects of administration of a massive dosage of prednisolone on lymphocyte functions in myasthenia gravis].
Topics: Adolescent; Adult; Child; Child, Preschool; Electrophoresis; Female; Humans; Leukocyte Count; Lympho | 1976 |
[The continuous treatment of generalized myasthenia gravis with small doses of prednisolone with or wihtout immunosuppressants (author's transl)].
Topics: Adult; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myasthenia Gravis; Prednisolone | 1976 |
Treatment of myasthenia gravis by long-term alternate-day prednisolone.
Topics: Adolescent; Adult; Aged; Child, Preschool; Cholinesterase Inhibitors; Female; Humans; Male; Middle A | 1975 |
[Treatment of severe forms of myasthenia with prednisolone and triamcinolone].
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Infections; Male; Middle Aged; Myasthe | 1975 |
[Experience in the treatment of acute fulminating myasthenia gravis].
Topics: Acute Disease; Adult; Combined Modality Therapy; Female; Humans; Male; Myasthenia Gravis; Plasmapher | 1992 |
[Myasthenia gravis and steroid therapy].
Topics: Adolescent; Adult; Child; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; M | 1992 |
[A case of a small thymoma associated with myasthenia gravis in which the tumor was reduced by corticosteroid therapy].
Topics: Adult; Humans; Male; Myasthenia Gravis; Prednisolone; Remission Induction; Thymectomy; Thymoma; Thym | 1992 |
[Possibilities of using enterosorption in the treatment of myasthenia gravis].
Topics: Adolescent; Adult; Azathioprine; Charcoal; Child; Combined Modality Therapy; Enterosorption; Eye Mov | 1991 |
Plasma C3c in immune-mediated neurological diseases: a preliminary report.
Topics: Autoimmune Diseases; Complement C3c; Follow-Up Studies; gamma-Globulins; Humans; Infusions, Intraven | 1991 |
Thyrotoxicosis with myasthenia--an unusual association.
Topics: Adult; Blepharoptosis; Carbimazole; Female; Humans; Myasthenia Gravis; Neostigmine; Prednisolone; Th | 1991 |
Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.
Topics: Adult; Drug Administration Schedule; Female; Humans; Male; Myasthenia Gravis; Prednisolone | 1991 |
[Tactical and technical errors in surgical treatment of patients with generalized myasthenia gravis].
Topics: Adult; Cholinesterase Inhibitors; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisolone; Preo | 1991 |
Long term treatment of myasthenia gravis with azathioprine.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Hypertension, Portal; Jaundice; Long | 1990 |
[Indicators of central hemodynamics and myocardial contractility function im myasthenic patients on glucocorticoid treatment].
Topics: Adolescent; Adult; Electrocardiography; Female; Glucocorticoids; Hemodynamics; Humans; Male; Middle | 1990 |
Unsuspected myasthenia gravis presenting as respiratory failure.
Topics: Azathioprine; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisolone; Respiratory Insufficiency | 1990 |
[Myasthenia gravis].
Topics: Animals; Autoantibodies; Edrophonium; Electromyography; Humans; Myasthenia Gravis; Plasma Exchange; | 1990 |
Pathogenesis and treatment of myasthenia gravis.
Topics: Autoimmune Diseases; gamma-Globulins; Histocompatibility Antigens; Humans; Lymphocytes; Myasthenia G | 1986 |
Bowel perforation in a patient receiving prednisolone for myasthenia gravis.
Topics: Female; Humans; Intestinal Perforation; Middle Aged; Myasthenia Gravis; Prednisolone; Sigmoid Diseas | 1989 |
[Tactics in the management of pregnancy and labor in myasthenia gravis].
Topics: Adult; Azathioprine; Cholinesterase Inhibitors; Combined Modality Therapy; Delivery, Obstetric; Fema | 1989 |
[Status of the hypophysis-adrenal cortex system during treatment with glucocorticoids by the method of intermittent (every other day) administration].
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Asthma; Drug Administration Schedule; Female; | 1986 |
Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis.
Topics: Autoantibodies; Azathioprine; Humans; Immunosorbent Techniques; Immunotherapy; Myasthenia Gravis; Pl | 1988 |
Long-term follow-up study of relapse in symptoms and reelevation of acetylcholine receptor antibody titers in patients with myasthenia gravis.
Topics: Autoantibodies; Follow-Up Studies; Humans; Myasthenia Gravis; Prednisolone; Receptors, Nicotinic; Re | 1988 |
[Long-term follow-up study of anti-acetylcholine receptor antibody titers and clinical symptoms in patients with myasthenia gravis].
Topics: Adolescent; Adult; Antibodies; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myasthen | 1988 |
Myasthenia gravis treated with ciclosporin.
Topics: Adolescent; Adult; Autoantibodies; Cyclosporins; Drug Therapy, Combination; Female; Humans; Kidney; | 1988 |
High-dose intravenous immunoglobulin for myasthenia gravis.
Topics: Child; Combined Modality Therapy; Eye Diseases; Female; Humans; Immunization, Passive; Immunoglobuli | 1988 |
[Variants of the pathogenetic therapy of myasthenia gravis].
Topics: Adult; Child; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Posto | 1987 |
Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis.
Topics: Adult; Cholinesterase Inhibitors; Combined Modality Therapy; Drug Administration Schedule; Female; F | 1987 |
Steroid responsive fibrosing alveolitis in myasthenia gravis.
Topics: Adrenal Cortex Hormones; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisolone; Pulmonary Alv | 1987 |
[An atypical form of juvenile myasthenia gravis associated with severe emaciation, muscle atrophy, ophthalmoplegia, bulbar signs and joint contracture].
Topics: Adolescent; Bulbar Palsy, Progressive; Contracture; Electrophysiology; Emaciation; Female; Humans; J | 1987 |
[Extracorporeal hemosorption in the intensive care of myasthenia].
Topics: Adult; Cholinesterase Inhibitors; Combined Modality Therapy; Critical Care; Dexamethasone; Female; H | 1986 |
[Features of the clinical picture, course and treatment of myasthenia in late middle-aged and aged persons].
Topics: Age Factors; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Combined Modality Therapy; Diagnost | 1986 |
[Effect of corticosteroids on the motor end-plate fine structure in experimental autoimmune myasthenia gravis rats and normal rats].
Topics: Animals; Dexamethasone; Motor Endplate; Myasthenia Gravis; Neuromuscular Junction; Prednisolone; Rat | 1985 |
Erythrocyte insulin receptor and glucose tolerance test in children treated with prednisolone.
Topics: Adolescent; Arthritis, Juvenile; Child; Erythrocytes; Female; Glucose Tolerance Test; Humans; Insuli | 1985 |
[Myasthenia gravis and malignant thymoma in pregnancy: a case report].
Topics: Adult; Cyclophosphamide; Female; Humans; Myasthenia Gravis; Postoperative Care; Prednisolone; Pregna | 1986 |
[Principles and limits of ACTH-cortisone therapy in neurology].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Cortisone; Dexamethasone; Epilepsy; Facial Par | 1969 |
Ocular response to corticotropin in myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Blepharoptosis; Eye; Eye Manifestations; Humans; Myasthenia Gravis; Oph | 1973 |
Adverse interaction between steroid hormones and anticholinesterase drugs.
Topics: Action Potentials; Animals; Anura; Cholinesterase Inhibitors; Dexamethasone; Drug Interactions; Edro | 1974 |
Complications associated with the radiotherapy of thymic tumours.
Topics: Adult; Edrophonium; Humans; Influenza, Human; Male; Myasthenia Gravis; Neostigmine; Pericarditis; Pn | 1973 |
[Massive prednisolone administration in myasthenia gravis--electrophysiological examination].
Topics: Administration, Oral; Adult; Female; Humans; Injections, Intravenous; Myasthenia Gravis; Prednisolon | 1973 |
Results of thymectomy in systemic lupus erythematosus: observations on clinical course and serological reactions.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoimmune Diseases; Complement System Proteins; Coombs | 1966 |
Myasthenia gravis, rheumatoid arthritis, vitiligo, and autoimmune haemolytic anaemia.
Topics: Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Heart Failure; Hemoglobinometry; Humans; Male; | 1971 |
[Therapy of oculomotor muscle paralysis].
Topics: Administration, Topical; Anti-Inflammatory Agents; Guanethidine; Humans; Myasthenia Gravis; Myositis | 1968 |